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the
returning
tide : 
How China, the world’s most 
populous country, is building 
a competitive research base
When China turned its back on the Cultural Revolution, it aimed to build a thriving 
capitalist sector. It got one. Now, it wants a world-class research enterprise. How far has 
it progressed in the biosciences, how did it get there, and how far does it have to go?
T
he meteoric rise of China and its 1.3 billion people is the 
story of the century. Change comes so fast that visitors 
looking for smoke-belching factories—the ￿  rst chapter 
in this tale—now have to look west. China’s prosperous east 
coast, meanwhile, is dominated by a less visible world of big 
business and high tech.
Biology  research  is  one  part  of  this  second  chapter  of 
knowledge-based innovation. It is being driven by a change in 
migration patterns. For 20 years, the educated elite of China 
have ￿  ed to the West (predominantly to the United States), 
becoming a signi￿  cant part of the workforce in US research 
laboratories. Finally, this ￿  ood is yielding a trickle of returnees. 
They  are  staf￿  ng  new  and  rejuvenated  institutions—just  a 
handful, to be sure. But in hindsight, establishing those ￿  rst 
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beachheads may have been the hard part. “As long as the politics 
are stable,” says Yixian Zheng (Carnegie Institution, Washington, 
DC), “I think China will become a very good place for science.”
￿￿￿ ￿￿￿￿￿￿￿￿￿
Beyond the neon-covered high rises of Shanghai and the bustling 
boulevards of Beijing, China remains a developing country. 
Half of its people still make their living from the land, and 
only 2.4% own a car.
But in this case, “developing” is a fact rather than a hopeful 
moniker. The Chinese economy has grown by 9.4% on average 
for each of the last 26 years. China is responsible for half of the 
world’s concrete use, and is now the world’s second largest 
energy producer and consumer. It does not, however, register on 
KEEPING THEM OUT NO MORE 
China’s opening to the outside marked 
the country’s scientiﬁ  c rebirth. 
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an innovation index of 24 countries devised by the Economist.
Changing that situation is a priority. “The government has a 
lot  of  money  to  spend  on  innovation,”  says  Shao  Feng  at 
Beijing’s National Institute of Biological Sciences (NIBS). “You 
have to be capable in that respect, otherwise you are just a big 
manufacturer. They have the money, and they want to spend it.”
It helps that many of China’s leaders were educated as engi-
neers at the prestigious Tsinghua University in Beijing. In 2003, 
notes Bruce Alberts (former head of the US National Academy of 
Sciences), the Chinese President Hu Jintao talked at a meeting of 
scientists and then stayed for 1.5 hours. Similar attention to sci-
ence from a US president is “hard to imagine,” said Alberts 
recently. “China is run by scientists and engineers, and they get it.”
China currently spends 1.23% of its gross domestic product 
(GDP) on research and development—a high proportion for a 
developing country, but about half that of many developed coun-
tries. The target announced in August 2006 by the government 
was 2.5% by 2020. “If you think about the growth in GDP,” says 
Chinese Academy of Sciences (CAS) Vice President Chen Zhu, 
“that amount is huge.”
Individual researchers are feeling the effects directly. “Each 
year  the  government  increases  the  money  in  research,”  says 
Wang Shengdian of the Institute of Biophysics in Beijing. One 
academic reports a 24-fold salary increase since 1998; others a 
nearly 100-fold increase in the size of start-up grants over the 
last 13 years. “These last ￿  ve years, Chinese science developed 
the fastest maybe in the world,” says Wang Shiqiang of Beijing 
University. “A new system was built up.”
The basis for these increases is twofold: the expansion of 
the economy; and the priority that China gives to scientists. In 
China, “people still respect scientists as a pillar of society,” says 
Mu-ming Poo (University of California, Berkeley, CA). As a 
result of this moral and ￿  nancial support, Yigong Shi (Princeton 
University, Princeton, NJ) encourages Chinese nationals to go 
back. “I see China as the next major opportunity,” he says.
But Shi does not think all is perfect in the Chinese science 
expansion. “I don’t believe it is occurring as fast as possible,” he 
says. “If you look at the vast resources, China hasn’t exploited 
them much. If China only had 500 students in the US they would 
be doing very well. But looking at the base they have to draw 
on”—an estimated 8,000 Chinese graduate students and post-
docs are working in US bioscience labs at any one time (1)—
“they are not that successful.”
The scale of the potential returns is evident from the situation 
in the US. In 1996, says Shi, the US had less than 10 full profes-
sors who had arrived from mainland China after the Cultural 
Revolution, but today there are 500–1,000. “That is a 100-fold 
increase,” he says. “But China’s recruitment has not picked up 
100-fold. It is in no way commensurate.”
China has many academics, but the number who are world-class 
is still low. By one estimate, there were only 500 “productive” 
biologists in China in 2004 (reference 2; a biologist was de￿  ned as 
“productive” if he or she published a certain number of medium-
impact papers). This compares to an estimated 40,000 productive 
biologists in the US, including 3,000 of Chinese descent.
Shi draws a similar conclusion. “Princeton has maybe 1,000 
faculty members,” he says. “How many at Tsinghua [University]  ★ ★
Key figures in this article
Opinions from the following people appear in multiple 
places in this article.
CHINA-BASED
CHEN Zhu is the only biologist who is also a 
vice president at the Chinese Academy of Sciences 
(CAS). He supports a balance between competitive 
NSFC-funded projects and MOST-funded 
infrastructure projects.
LU Yongxiang is a former engineer who was 
elected as the president of the Chinese Academy of 
Science in 1997. The following year he initiated the 
Knowledge Innovation Program (KIP), which 
revolutionized CAS operations.
RAO Zihe was until recently the director of the 
CAS Institute of Biophysics in Beijing, which he 
revitalized during his three-year tenure. He is now the 
president of Nankai University in Tianjing. He is 
supportive of the large group projects funded by MOST.
UNITED STATES–BASED
Bai LU (NIH, Bethesda, MD) is a neuroscientist 
who from the mid-1990s has advised on science 
policies and CAS reforms; more recently he helped 
establish better peer review at the NSFC.
Mu-ming POO (University of California, Berkeley, 
CA) was a past chair of the Department of Biological 
Sciences and Biotechnology at Tsinghua, and founded 
and now directs ION in Shanghai.
Yi RAO (Northwestern University, Chicago, IL) was 
involved in the creation of ION, initiated a major 
graduate course in Shanghai and Beijing, and now has 
a lab at NIBS. With Bai Lu, he coauthored the banned 
Nature article that advocated for more merit-based 
science funding in China.
Yigong SHI (Princeton University, Princeton, NJ) is 
a structural biologist who is also an adjunct professor 
at his alma mater, Tsinghua. Several of his former 
postdocs have faculty positions in China. Shi stresses 
the importance of better teaching in China.
Xiaodong WANG (University of Texas 
Southwestern Medical Center, Dallas, TX) is a founding 
codirector of NIBS in Beijing. The other codirector is 
Xingwang Deng of Yale University, New Haven, CT.
Key figures in this article
would qualify for full professorship at Princeton? I doubt the 
number is over 10.” By general agreement, the roster of good 
researchers falls off even more sharply outside of major centers 
such as Beijing and Shanghai.
But the numbers build daily. Many of the researchers pro￿  led 
here are such recent arrivals that they have not yet had time to 
publish from China. Even many in China are unaware of these 
recent arrivals’ presence and past publication records.★
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Imperfections  notwithstanding,  mainland  China  remains  a 
stunning  example  of  how  to  kick-start  a  research  enterprise 
(progress in Hong Kong and Taiwan will not be covered in this 
article). Development is a dif￿  cult, messy business littered with 
far more failures than successes. To see any measure of progress 
in an area as challenging as high-level biology research is aston-
ishing and deserves a close inspection to see what went right.
￿￿￿ ￿￿￿￿￿ ￿￿￿￿ ￿￿￿￿￿ ￿￿￿￿￿￿
So many things in China—the size of the population, the pace of 
change and economic growth, even the scale of the scenery—
seem more dramatic than in any other country. The generational 
differences driving changes in Chinese science are no exception.
“There is a lot of energy in China—everyone wants to move 
ahead,”  says  Junying Yuan  (Harvard  University,  Cambridge, 
MA). “The biggest limitation is still the brain drain during the 
Cultural Revolution. They are missing one generation.”
During China’s Cultural Revolution (1966–76), universi-
ties  were  emptied  and  professors  and  students  sent  to  the 
countryside for “re-education.” Research and economic con-
ditions  remained  hostile  enough  to  force  most  researchers 
overseas for a long time afterwards.
Thirty years later, human resources come in the form of a 
distorted pyramid, with a very wide base but very narrow top. At 
the peak of this pyramid is a tiny group of leaders. These are the 
few people who managed to do three things: ￿  rst, clamber back 
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Descriptions of modern China are usually 
out of date by the time they are printed. 
With this caveat in mind, the following is 
a broad brush outline of some key char-
acteristics of the Chinese scientiﬁ  c system.
GEOGRAPHY The best biology 
research is heavily concentrated in 
Beijing, the source of most funding, and 
Shanghai, arguably the most cosmo-
politan mainland city. Exceptions include 
a primate research center in Kunming in 
the south. New developments are being 
promoted in areas that have a lot of 
economic activity but little or no science. 
These include a proteomics center in 
the Pudong area of Shanghai and a 
new biomedicine institute in Guangzhou, 
near Hong Kong.
THE ACADEMY Traditionally, the 
focus of Chinese universities has been 
on teaching. The best research has been 
concentrated instead in the institutes of 
the Chinese Academy of Sciences 
(CAS), which tend to be more ﬂ  exible in 
adjusting to new priorities. CAS also 
operates as an exclusive club of respected 
scientists. Election to the position of CAS 
academician brings with it an extraordi-
nary level of deference that far exceeds 
the respect shown in the West to a mem-
ber of the US National Academy of 
Sciences or the UK Royal Society. One 
of the CAS vice presidents, Chen Zhu, 
is a biologist himself and thus the voice 
for other CAS biologists.
INSTITUTIONS Shanghai has a cluster 
of CAS institutes including the Institute of 
Neuroscience (ION), Institute of Biochem-
istry and Cell Biology (IBCB), and the new 
Institute of Health Sciences (IHS). Shang-
hai’s most famous university is Fudan 
University. In northwestern Beijing are 
the Harvard and MIT of China: Beijing 
University (also known as Peking University 
or, colloquially, as Beida) and Tsinghua 
University (pronounced, and sometimes 
spelled, as Qinghua University). The CAS 
Institute of Biophysics (IBP) is also nearby, 
and further north is the recently formed 
National Institute of Biological Sciences 
(NIBS), which is independent of both the 
CAS and university systems.
THE EXPATRIATES Chinese-born 
but US-resident academics have been 
signiﬁ  cant in the development of biology 
research in China. See the “Key Figures” 
box for some examples.
MONEY CAS institutes have some 
stable funding of their own, but even 
CAS researchers require additional 
funding sources. The dominant presence 
is the Ministry of Science and Technology 
(MOST), which has a penchant for big 
projects. It has been widely criticized for 
basing grants on politics rather than merit. 
The National Natural Science Foundation 
of China (NSFC) has a proper grant 
review system, but a US$425 million 
budget compared with the US$1.7 billion 
disbursed by MOST. Additional money 
comes from a patchwork of provincial, 
city, and local government initiatives.
THE WORKFORCE Ph.D. students are 
the main workforce in the labs. The best 
undergraduates from the best universities 
often do their Ph.D.s overseas (most in 
the US), but there are plenty of students 
from more distant universities to take their 
place. Large numbers of technicians and 
Master’s students also contribute; postdocs 
are almost all done overseas.
Science in mainland China: a primer Science in mainland China: a primer
TOWERING FUTURE  Shanghai’s Jin Mao Tower, the fourth highest 
building in the world, is a symbol of China’s ambitions.★
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into  the  educational  system  immediately  after  the  Cultural 
Revolution; then, ￿  nagle their way into some overseas experi-
ence; and ￿  nally, take the gamble to return to a very immature 
Chinese research system.
Next come the more recent returnees. The ￿  rst of these re-
turnees were still taking a very big risk, and the emphasis in 
this early period was more on short-term visits, with research-
ers retaining their primary faculty appointments in the US or 
Europe. Some of those part-timers have operated as a kind of 
Greek chorus during China’s scienti￿  c development, prodding 
the Chinese government to commit to basic science and to 
allow scientists to determine the agenda.
Those who actually made the jump 
to  full-time  residence  in  China  were 
often rewarded, despite their young age, 
with  signi￿  cant  leadership  positions, 
including directorships of new institutes 
(3). “People in their early thirties are 
too young to be controlling major scien-
ti￿  c decisions,” says Yuan, “but there is 
nothing [else] you can do.”
With every year that goes by, the size 
of the gamble involved in returning to 
China lessens. More and more Chinese 
citizens  are  embarking  on  postdocs  in 
the US or Europe with no intention of staying overseas.
Their return is fuelled by the wide base of the pyramid: a 
vast supply of eager students. The offspring of 1979’s one-
child policy have streamed into universities. University and 
college enrollment tripled in China between 1995 and 2003 to 
reach  11  million.  Of  these  students,  “the  brightest  young 
people still go into science and technology rather than busi-
ness and law school,” says Poo.
The results for returning PIs are striking. Four months after 
arriving at the Institute of Biochemistry and Cell Biology (IBCB) 
in Shanghai, Chen Degui already has four students and three 
technicians. It took Gao Shaorong of NIBS only one year to 
accumulate his eight graduate students and ￿  ve technicians. His 
story is not unusual.
As for the students, their motivations vary. Some talk about 
scienti￿  c curiosity but others are more matter-of-fact. “It’s a 
job,” said two students, asked independently. Still others see it as 
a career that might allow them to experience life overseas.
Finally,  there  is  the  Chinese  belief  in  the  transformative 
power of learning, especially for the many students who grew up 
in the countryside. Lan Rongfeng is now a graduate student at 
Beijing University, but he grew up in a village of 70 farmers in 
Zhejiang province. “For people in the villages,” he says, “educa-
tion can change their life.”
￿￿￿￿￿￿, ￿￿￿￿ ￿￿￿￿￿￿ ￿￿￿ ￿￿￿￿￿￿￿￿
After the Cultural Revolution, Chinese science needed an update 
from outside. The government had to send people out of the 
country,  trusting  that  some  would  return.  “I  remember  what 
[Chinese leader] Deng [Xiaoping] said at the beginning of the 
reform,” says Chen of CAS. “If just one-tenth come back it 
should be considered a success.”
Key Laboratories, Normal 
Universities, and other 
translation idiosyncrasies
Fluid Chinese-to-English translation is always a 
challenge, and China has its fair share of exciting 
attempts at English (e.g., a “Fall down carefully” caution 
sign, and an “escaped” (i.e., wild) mushroom restaurant). 
But translation is particularly difficult when dealing 
with the collectivist-style government language that 
still litters China. The meaning of “State Key Laboratory” 
is somewhat clear—it is an important, state-sanctioned 
lab—even though somehow it doesn’t sound quite right.
The early Chinese communist governments used 
such language in subdividing the education sector. 
According to Soviet principles, each university was 
restricted to a single task, and there was one such 
university in each region. Thus, each major city had a 
“Normal University” to educate teachers, a “Jiaotong 
University” to study transportation and communication, 
and a “Military Medical University” for medicine. In 
general, these universities have now broadened their 
faculty to cover all disciplines, but the original, slightly 
odd names remain.
Key Laboratories, Normal 
Universities, and other 
translation idiosyncrasies
CULTURAL REVOLUTIONARY  Mao emptied the universities 
40 years ago, but the effects are still being felt today.
Every year 
the size of 
the gamble 
involved in 
returning 
to China 
lessens.★
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compete with each other for resources and demonstration of 
achievement,” said one recent report (4).
They remain, however, a select few. “We’re the ￿  rst group 
that came to the US and got Ph.D.s from reasonably good 
institutions,” says Bai Lu (NIH, Bethesda, MD), who arrived 
in the US in 1985. “And the more you do, the more people ask 
you to do. I hope more people will get involved.”
The Chinese government alternately seeks this group out as 
valuable  advisers  and  avoids  them  as  irritants.  The  China 
Voices incident was clearly an example of the latter. It started 
with  good  intentions:  Nature  had  published  a  supplement 
about China and wanted to publish a follow-up called China 
Voices II, initially in Chinese and later in English. In 2004, Yi 
Rao (then at Washington University, St Louis, MO), Lu, and 
Tsou Chen-Lu (then at the CAS Institute of Biophysics [IBP; 
Beijing], and recently deceased) 
wrote an article for the supple-
ment that was “a little bruising,” 
says Princeton’s Shi. It cited in-
effective  and  political  decision 
making at the Science Ministry 
and called for its effective gut-
ting (5). A week after publica-
tion, the article and entire sup-
plement was banned in China.
Banning  stopped  nothing.  “It 
was all over the place—from very 
high up to graduate students,” says 
Lu.  The  posted  article  attracted 
But ￿  rst they had to ￿  nd a way to leave. A critical step for 
biologists was the establishment of the China–US Biochemistry 
and  Molecular  Biology  Examination  and  Administration 
(CUSBEA) by Ray Wu of Cornell University (Ithaca, NY). 
The outside world did not know what to make of a ￿  ood of 
unsolicited applications from mainland China, but from 1982 
to 1989 CUSBEA’s standardized test helped smooth the path 
to US universities for 425 mainland Chinese students.
CUSBEA students made it easier for those who later ap-
plied independently. Based on the CUSBEA precedent, the 
main  ￿  ow  of  graduate  students  continued  to  go  to  the  US 
rather than Europe.
Most graduates from the CUSBEA program (such as Xiaodong 
Wang and Chen Ling; see below) did not immediately return 
to China. “Then, if you went back to China you pretty much 
didn’t do science effectively,” says Carnegie’s Zheng.
The expatriates did, however, mature into a kind of external 
independent advisory board for Chinese bioscience. Of￿  cial 
government language evolved in recognition of realities: “return 
and serve the country” (huiguo fuwu) became simply “serve 
the  country”  (weiguo  fuwu),  while  the  government  would 
“only  seek  to  utilize,  not  possess”  (danqiu  suoyong,  buqui 
suoyou) the expatriates (4).
The expatriates have the security and prestige of tenured 
employment,  mostly  in  the  US,  and  thus  an  extraordinary 
level of political independence even when acting within China. 
They “have become a new political constituency for whom 
special policies have been designated, institutes set up, re-
sources  provided,  and  for  which  government  departments 
SILENCED VOICES  An article 
coauthored by Yi Rao stirred 
controversy in China.
What’s in a name?
Beijing  taxi  drivers  who  are  ﬂ  uent  in 
English still seem to be the stuff of legend, 
but within Chinese research institutions 
English  is  widespread.  At  the  better 
universities a proportion of the technical 
classes  are  taught  in  English,  and  a 
majority of the more accomplished pro-
fessors  have  spent  signiﬁ  cant  time  in 
English-speaking countries.
The  Chinese  language  remains, 
however, an immeasurably rich cultural 
resource. One area where English is a 
particularly poor substitute is with names. 
The  English  transliterations  of  Chinese 
names not only lack the poetic meanings 
of the written originals, but also obliter-
ate  any  clues  as  to  what  tones  (e.g., 
rising or falling) should be used in pro-
nouncing the name. This leaves session 
chairs at conferences struggling to pro-
nounce correctly the names of less-familiar 
Chinese scientists.
Mutual  confusion  also  surrounds 
the identiﬁ  cation of family names. Many 
Chinese, such as the CAS President Lu 
Yongxiang, have three-syllable names. 
In these cases, the isolated syllable (Lu) 
is easily identiﬁ  able as the family name 
and the remainder (Yongxiang) as the 
personal  name.  The  same  trick  fails 
with names such as that of CAS Vice 
President Chen Zhu. Here both names 
are  single  syllables,  and  sometimes 
both are potential surnames. Email ad-
dresses are often not standardized and 
so yield no clue.
Of course there would be no problem 
if Chinese names were always ordered, 
as they have been historically, with the 
family  name  ﬁ  rst.  But  many  scientists 
based in China switched that order when 
they did Ph.D.s or postdocs in the West, 
or do so now when publishing or to ease 
other interactions with Western scientists. 
For the purposes of this article, we will 
use the traditional Chinese ordering for 
any scientist currently based primarily in 
China, but the Western order for those 
working in the West.
DISAPPEARING TRADITION  The embrace 
of English leaves the richness of written 
Chinese behind.★
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2,000 online comments in one day and, says Lu, “the vast major-
ity were supportive of our views.”
Poo agrees that often the expatriates are speaking for the 
majority. “The polarity of opinions,” he says, “is not between 
scientists inside and outside but between the majority of scien-
tists and a few administrators and scientists in power who 
bene￿  ted from the present system.”
The burden of criticism often falls on the expatriates because 
those based in China, especially the young returnees, are not 
willing to speak up. For this article, there was an unusually high 
level of concern among many of the China-based interviewees 
who were asked to talk publicly about policy issues. Their 
concern appeared to be far more about how their colleagues 
would react than about any possible of￿  cial rebuke.
Generally such matters are felt to be handled much better in 
private.  “Chinese  don’t  like  confrontation,”  says  Shi.  “When 
things turn confrontational they get worse.”
But some issues such as funding (see below) affect far more 
than the private group that may be able to debate them. How to deal 
with these issues once they reach the press is an evolving challenge 
in Chinese science. Leaving the role of public critic in the hands of 
expatriates is problematic: such outsiders may be resented by those 
who have worked in China for many years, including the days 
when funding was far more scarce, and who now deal with the 
realities of Chinese bureaucracy every day.
Despite the public spat, Lu continues to be an often-consulted 
adviser on science and technology policy. “I’ve made my voice 
heard,” he says. “I wouldn’t say it’s been completely effective. 
… Some of the ideas have been taken, but I don’t think they like 
[to see] these ideas on paper, especially in foreign journals.”
P￿￿￿￿￿￿￿￿ ￿￿￿￿
Far less controversial, and increasingly common, have been the 
research collaborations between US- and China-based Chinese 
biologists. Asked if she has such a collaboration, Harvard’s Yuan 
asks, “who doesn’t?”
These activities are the ￿  ip side to the expatriates’ role as 
commentator; they get experience within the Chinese system as 
research advisers, teachers, and even institute directors.
Zheng, for example, visits Zhu Xueliang’s lab at the IBCB in 
Shanghai for two one-week trips each year. For 16 hours a day 
she discusses projects and the drafts of papers with students.
Yuan has more regular contact with her four students at the 
CAS Institute of Organic Chemistry in Shanghai. In a “mutually 
bene￿  cial” collaboration with CAS principal investigator (PI) 
Ma Dawei, the students provide Yuan with compounds to test in 
her assays, and she introduces them to cell biology. “The screen-
ing is just as advanced as in the US but often they don’t have the 
[suf￿  ciently  interesting]  projects,”  says  Yuan.  She  conducts 
group meetings using Skype and data sent by ftp, but regrets she 
cannot “see the primary data through the microscope” as she is 
used to doing in her US lab.
Rao, who is now based at Northwestern University (Chicago, 
IL), has no such misgivings about his outpost of 20 people at 
Beijing’s NIBS. He visits the lab 10 times a year, and communi-
cates with lab members via Skype and Googletalk every day. 
“I’m a hands-off person,” he says. “I run the lab here [in the US] 
hands-off. Sometimes, I ￿  nd I run the lab in China more than the 
lab here.” He stresses that expatriates like him have not just been 
commenting, but doing.
￿￿￿￿￿￿￿￿ ￿￿￿￿ ￿￿￿￿￿￿￿￿￿
The NIBS lab is not Rao’s ￿  rst lab in China. In 1996, he, Lu, and 
Lin Mei of the University of Virginia, Charlottesville, set up a 
joint lab in the CAS Brain Institute in Shanghai. The lab’s suc-
cess inspired them in 1998 to propose a new Institute of Neuro-
science (ION), with Lu’s former mentor Mu-ming Poo (then at 
the University of California, San Diego) as part-time director.
“Because the economy was doing well, they were ready to do 
basic science,” says Poo. By contrast, “20 years ago at Tsinghua 
I knew they were not ready.”
Poo had de￿  nite ground rules. 
“I decided it would be dif￿  cult to 
promote [neuroscience in China] 
without a new structure,” he says. 
“The old institutes have old tradi-
tions that are hard to get rid of.”
Many of those traditions cen-
tered  on  hiring  and  ￿  ring.  Poo’s 
involvement  was  contingent  on 
him being given broad powers to 
hire who he wanted and to institute 
a uniform evaluation system. “Our 
review is rigorous, and that is how 
Harvard’s Junying Yuan 
collaborates with a chemistry 
institute in Shanghai.
LOOK AWAY  Chinese politicians ﬁ  nd it hard to ignore suggestions 
from overseas.★
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we are doing so well,” he says. “We ￿  red people who refused to 
be reviewed, including an academy member.” This is in a country 
where, Rao says, “members of CAS are held to be gods.”
Not surprisingly, “the initial establishment was problematic,” 
says Rao. ION’s inauguration date coincided with the closing of 
the moribund, but heavily populated, Institute of Physiology, and 
there was general discontent that ION would divert funds away 
from other neuroscientists. A huge meeting was organized to 
protest against ION, students threatened to demonstrate, and the 
central government got nervous. Others voiced their discontent at 
a meeting in Hebei. “There were several movements to get rid of 
me,” says Poo. “I didn’t think I could last so long.”
At times, the founders found safety in numbers. “There were 
different times when one or two of 
us wanted to pack up but the oth-
ers  said  no,”  says  Rao.  But  any 
doubts  that  Poo  might  have  had 
are long gone. “Those hard feel-
ings are forgotten now, I hope,” he 
says. “The institute was the right 
thing to do.”
“After three or four years,” says 
Rao, “it was uniformly respected, 
and  it  has  never  really  diverted 
funds  from  anyone.”  (See  below 
Mu-ming Poo met resistance 
when forming ION.
for more on funding.) Poo claims modestly that for recruitment 
“we are competing with second-tier universities in the US.” For 
China in 1999, or even in 2007, this is no mean feat.
Poo “has put in an enormous amount of energy,” says Yuan 
at Harvard. More is to come. ION now has 15 labs and is aim-
ing for 30 within the next few years, with Poo hoping to ￿  ll in 
de￿  cits in cognitive and systems neuroscience. Poo is based at 
the  University  of  California,  Berkeley,  but  still  works  in 
Shanghai, for free, one week a month. “I will continue,” he 
says, “until they ￿  re me.”
￿￿￿ ￿￿￿￿ ￿￿￿￿
ION was not on its own in trying to recruit foreign-based talent. 
Government-backed programs provided signi￿  cant incentives. 
The CAS “hundred talents” program began in 1994 and the Min-
istry of Education’s Changjiang Scholars program in 1999. The 
incentive programs have, ironically, strengthened the motivation 
for young Chinese researchers to leave the country initially so 
that they can subsequently return and receive the incentives.
Recipients in both programs mostly come from overseas and 
receive salaries 2-10–fold higher than standard Chinese profes-
sorial salaries; an ION starting salary is now ∙US$20,000 per 
year plus an initial US$65,000 to help with housing. Even with 
Shanghai’s booming real estate market, this puts ION PIs in a 
better position than many PIs in expensive foreign cities. The 
out glial subtypes and functions. Many previous investigators have 
assumed that the nervous system phenotypes of their knockouts 
arose from neuron defects, but Duan is not so sure.
Duan’s colleague, Shu Yousheng, is also taking a new look 
at a well-studied problem by investigating chronic pain not in 
the spinal cord but the cortex. Two other 
projects focus on how neural networks 
with stable, balanced activity (7) might 
be  turned  on  and  off,  and  how  sub-
threshold signals that modify action po-
tentials (8) might be changed in disease 
states. Finally, he is testing how pyramidal 
neurons  integrate  two  very  different 
types  of  information:  memory-related 
inputs from their apical dendrites; and 
visual and auditory updates that arrive 
via their basal dendrites.
1.  Xiang, Y., et al. 2002. Nat. Neurosci. 5:843–848.
2.  Yuan, X.B., et al. 2003. Nat. Cell Biol. 5:38–45.
3.  Li, Y., et al. 2005. Nature. 434:894–898.
4.  Yang, Y., et al. 2003. Proc. Natl. Acad. Sci. USA. 
100:15194–15199.
5.  Zhang, J.M., et al. 2003. Neuron. 40:971–982.
6.  Ge, W.P., et al. 2006. Science. 312:1533–1537.
7.  Shu, Y., et al. 2003. Nature. 423:288–293.
8.  Shu, Y., et al. 2006. Nature. 441:761–765.
For Duan Shumin, a Ph.D. (in Kyushu, Japan) and two postdocs 
(at the University of Hawaii and University of California, San 
Francisco) were not the end of his training. That came only once 
he became a co-PI with Mu-ming Poo at Shanghai’s ION.
“When I came back to China, I had a good training in 
techniques,” he says. “But when I 
worked with Mu-ming I learned to 
think more critically and found im-
portant things to do. Then I learned 
my own way, my own direction. If 
you can say I succeeded, that is the 
most important thing.”
In  collaboration  with  Poo, 
Duan revealed that chemokines (1) 
and  Rho  family  proteins  (2)  help 
guide  neural  growth  cones.  (Yuan 
Xiao-bing, the ﬁ  rst author of the lat-
ter paper, is now also a PI at ION. He recently reported that 
TRPC channels help guide growth cones [3].)
Duan then turned to glia, which he found make D-serine 
to support neuronal synapse strengthening (4) and ATP to 
suppress neuronal synapse transmission (5). Direct synapses 
between neurons and certain glia were, Duan found, subject 
to a unique form of activity-dependent modiﬁ  cation (6).
Now, Duan is interested in how glia package and 
release their messengers. He also hopes to selectively knock 
A second guidance
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According to the rules of the Institute of Neuroscience (ION) 
in Shanghai, Yu Xiang has four years to prove herself as a 
ﬁ  rst-rate principal investigator. That is okay by her. “If I can’t 
do it,” she says, “I’d rather leave as soon as possible.”
Yu’s four-year contract, and the one-year contracts of 
those working under her, are a huge change. Every worker in 
the Chinese education and academic system, from technician 
to professor, used to be guaranteed lifetime employment from 
the ﬁ  rst day onwards. This cultural change is one of many that 
the ION has helped bring to China.
Yu has already proven herself at Cambridge University 
in the UK and at Stanford University in California. This is, 
however, her ﬁ  rst stint as an independent lab head. It is not 
without its challenges. With few postdocs in sight in China, 
“it means I have to work a little harder,” she says. “It means I 
am the lab head and senior postdoc.”
Her focus is on the intersection 
of neural morphology and activity. In 
her previous work, Yu showed that 
activated nerves grew more complex 
and longer dendrites, and that this 
operated via β-catenin (1). Now, she 
has found that the cell compensates 
for the enlarged dendritic tree by 
making smaller synapses. She is 
keen to test whether these pathways also apply in vivo and 
how they translate into altered connections between neurons 
during development and disease.
1.  Yu, X., and R.C. Malenka. 2003. Nat. Neurosci. 
6:1169–1177.
incentive awards include start-up packages of US$242,000 over 
three years—half or less of what might be expected in the US, 
but in China the labor costs are far lower.
Returnees must often create a scienti￿  c culture almost from 
scratch. Many Chinese institutions lack practices usually taken 
for  granted:  regular  group  meetings;  journal  clubs;  visiting 
speakers; seminar courses and lab rotations for students; and col-
legial interactions between research groups. ION pioneered a 
number of these practices in China 
and has encouraged their spread 
to other locations.
But the opportunities for per-
sonal  reinvention  are  also  sig-
ni￿  cant. Pei Duanquing (Guang-
zhou  Institute  of  Biomedicine 
and  Health)  previously  had  a 
faculty  position  in  the  US  but 
wanted  to  switch  to  stem  cell 
work. “I realized it’s very dif￿  -
cult to switch careers in the States,” he says. “Coming back to 
China allows you to do new things.” Other returnees were 
driven from the US by the tight NIH funding, or because they 
could not recruit enough students.
Although the number of returnees is still small for such a 
large country, the number of world-class institutions for return-
ees to join is even smaller. These institutions have been ￿  lling 
their vacancies at breakneck speed, leaving fewer opportunities 
for late-comers. Now, “a lot of postdocs in the US want to come 
back but cannot get a good opportunity,” says Wang Shengdian 
of Beijing’s IBP. “Now, the opportunities will be less and less, 
and the standard will become higher and higher.”
There is, however, a vast potential outlet for returnees. “There 
are  very  few  [successful]  institutes  like  IBP  in  China,”  says 
Wang. “But there are a lot of universities that need good people.” 
At Beijing Normal University (BNU), Cong Yusheng is “trying 
to recruit people now,” he says. “I got a lot of applications. There 
are a lot of successful people in the US trying to return.”
BNU is better off than most universities: it is surrounded 
by some of the best research institutions in China, and it is in 
Beijing, a well-funded city on the well-funded east coast. It will 
take more economic development in China, however, before the 
myriad universities outside of Beijing and Shanghai get more 
funds and become attractive to returnees.
Even once the money arrives, there would be another prob-
lem. “Institutes like IBP focus on research and give PIs a lot of 
support,” says Wang. “But, in the universities, the administration 
is not very good. Even if they have money, they don’t use it for 
research. Instead, they build a very good building.” To change 
such a culture, he says, there is one crucial ingredient: “The 
leader is very important.”
￿￿￿￿￿ ￿￿ ￿￿￿ ￿￿￿￿￿￿
Wang’s focus on leadership is no 
coincidence.  IBP,  where  Wang 
works now, was revived by the 
strong  leadership  of  structural 
biologist Rao Zihe, building on 
the  work  of  his  predecessor 
Wang Zhixin.
Rao was 16 when the Cultural 
Revolution began. “It was a very 
dif￿  cult period but probably the 
most important period for me in 
my  life,”  he  says.  “I  suffered.  I 
never had experience working in 
the countryside, and the ￿  eld work 
was so hard—you cannot imagine 
how hard.” After all this time, he says, “I still know how to farm.” 
But, more importantly, he says, “it made me physically strong and 
mentally very strong so I can face any challenge.”
As the Cultural Revolution waned, Rao was one of 200 stu-
dents chosen, mostly from the countryside, to have their university 
attendance sponsored by CAS. After graduation, he did a Master’s 
at IBP, a Ph.D. at Melbourne University in Australia, and a postdoc 
Shaping up
YU XIANG
Rao Zihe has helped build 
protein structure and function 
studies at IBP.
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at Oxford University in the UK. His ￿  rst project at Oxford was a 
struggle with an in￿  uenza protein whose structure has still not 
been solved, but he was also “lucky” to be working on the struc-
ture of EGF. This factor was thought to be unstructured, but Rao 
showed otherwise (6). Soon afterwards came a structure of an 
SIV matrix antigen (7).
“I always wanted to come back,” says Rao. “I think I pre-
pared my mind to come back and do something even better 
than [what I did] outside.”
But the timing had to be right. “I always tell my students: if you 
don’t get any good results, don’t come back—no one will pay atten-
tion to you,” he says. “I was so excited when I got my result and 
got my Cell paper” but he was not yet ready to return. “But when I 
got my Nature paper I made an 
immediate decision to come back.”
Rao initially avoided IBP, as it 
lacked  any  molecular  biology  or 
work on protein function, and his 
in￿  uence  there  would  have  been 
complicated by the presence of his 
former supervisor. In 1996, he set 
up a lab at nearby Tsinghua Uni-
versity.  Finally,  in  2002,  CAS 
President Lu Yongxiang asked Rao 
to be the director of IBP.
CAS  initially  gave  Rao  40 
million RMB (∙US$5 million) to set up a core research unit devoted 
to protein structure and function. IBP’s proteomics center has 
robots for spot picking, and fancy mass spectrometers; the insti-
tute’s shared lab space has a sea of shakers, two protein crystal-
lization machines, and a room packed with 10 HPLC machines.
Along with the equipment came people: 13 new faculty 
hires in Rao’s ￿  rst year alone. (Some came in the wake of re-
cruiting  efforts  by  Rao’s  predecessor,  Wang  Zhixin.)  Liu 
Yingfang, for example, arrived after determining structures of 
TNF family ligands and receptors (8, 9). Xu Tao, by contrast, 
is using his previous work on exocytosis (10, 11) to focus on 
the  regulation  of  insulin  release.  Meanwhile,  Rao  had  his 
own triumph with a publication in Cell (12). This and another 
paper, authored earlier in 2005 by students under the super-
vision of Yi Rao (13), represented the ￿  rst two Cell papers 
from teams based in mainland China.
The 36-year-old Xu has now replaced Rao at the helm of IBP. 
After just three years of leading IBP, Rao “was ordered” to take 
on the presidency of Nankai University. The university is south-
east of Beijing in the economic powerhouse city of Tianjing. Rao 
explains that “[Former President] Jiang Zemin made Shanghai 
Pudong”—a booming techno-￿  nancial area. “The current gov-
ernment wants Tianjing to become like this.”
Rao Zihe, it seems, is their man for the job.
￿￿￿ ￿￿￿￿￿￿￿￿￿ ￿￿ ￿￿ ￿￿￿￿￿￿￿￿￿
ION was created as a new institute, and the reincarnated IBP 
looks almost new. Poo at ION and Rao at IBP took advantage of 
that newness: they had the freedom to institute revolutionary 
new policies and to hire a handpicked new faculty roster.
But many universities and institutes must undertake a task 
that is perhaps even more challenging: evolution from an exist-
ing structure and faculty base. The two current deputy directors 
at Shanghai’s Institute of Biochemistry and Cell Biology (IBCB), 
Zhu Xueliang and Jing Naihe, have seen that process in action.
IBCB was born in the 1950s as two separate biochemistry 
and cell biology institutes. The changes that transformed these 
institutes and the rest of CAS began in earnest with the election 
of CAS President Lu Yongxiang in 1997 and the start of his 
Knowledge Innovation Program (KIP) in 1998. “That was the 
most dif￿  cult and exciting time,” says Zhu.
Lu was faced with an institution in crisis. Soviet-style, insti-
tute-based research at CAS was clearly being outperformed by 
university-based research in the US and Europe. As a result, 
“people were arguing about whether CAS needed to exist,” says 
Zhu. “From 1999, we reprogrammed the whole system.”
IBP’s new director, Xu Tao.
SHANGHAI’ S WONDER  The Pudong area is part of China’s shiny new future.
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Under the KIP proposal, the 123 CAS institutes were to be 
reduced to 80 (the ￿  nal number reached in 2005 was 89) by spin-
ning off commercial enterprises and amalgamating redundant 
institutions. Furthermore, the 59,000-strong workforce would be 
halved even as graduate student numbers and the overall CAS 
budget both doubled.
The merger that created IBCB occurred in 2000. Within two 
years, the 700 employees, including more than 60 administrators, 
had been cut to fewer than 200 employees and 12 administrators. 
PIs were not ￿  red, but retirement at 65 was enforced (allowing the 
recruitment of 16 new, young PIs since 2000), and commercial and 
administrative positions were spun off.
PIs now had to pass two evaluations given every four years 
before their positions were secure, and the institute’s own money 
was divided up based on per-
formance.  (Before,  each  lab 
got  roughly  an  equal  share.) 
Other staff were put on 2-year 
contracts, and PIs were given 
the power to hire and ￿  re their 
own staff. “This may not sound 
surprising, but in China we are 
supposed to be socialist, so it 
was quite hard,” says Zhu. It is 
also, he says, one of the rea-
sons why CAS has ￿  ourished 
in the 21st century relative to 
the universities.
CAS also emphasized bringing in younger directors. From 
1991 to 2003, the average age of directors and their deputies fell 
from 56 to 47. The newcomers, with better publication histories, 
were not afraid to introduce evaluations based on publishing 
papers in internationally recognized journals.
Wang Shengdian at IBP; the cranes behind are building the 
2008 Olympic village.
Opportunity, but with a price
Switching from Johns Hopkins University (Baltimore, 
MD) to the IBP in Beijing has broadened Wang 
Shengdian’s options. His past work was restricted to 
basic research on lymphocyte costimulatory mole-
cules (1, 2), but now he is branching out into both 
lab and clinical work on HBV and tumor immuno-
tolerance. “In the US, you cannot do something that 
is not related to your lab’s major interest,” he says. 
“But here I can do anything. Here, you have a lot of 
students who can try out your ideas.”
Nothing comes for free, however. His students, 
though plentiful and hardworking, need a lot of 
supervision. “In China, most students only know how 
to get data,” he says. This is a task well suited to 
postdocs, he says, but for students “the major task 
is to learn how to study.” Unfortunately, says Wang, 
“most Chinese professors don’t get students to read 
papers, and are too busy to have a journal club or 
even lab meetings. But, in our lab, we have journal 
club every week.”
Wang’s colleague at IBP, Tang Jie, puts a similar 
emphasis on student-driven design of experiments, 
even if the students prove only a minor hypothesis. 
“After this cycle, they are ready to do science,” he 
says. “Although the paper may not be a high-impact 
paper, the training is more important.”
China has other advantages for a clinician 
like Wang. “In China, there are a lot of patients 
as a resource,” says Wang, who has contacts at 
Beijing Union Medical College, his Ph.D. alma 
mater. “Here, I can have a lot of collaborations 
with doctors and other researchers.” Tang has 
also escaped restricted choices in the US, where 
he had to alternate between jobs in either basic 
research or industry. “Here,” he says, “I can do 
both. I have more freedom.”
1.  Wang, S., et al. 2002. J. Exp. Med. 195:1033–1041.
2.  Wang, S., et al. 2003. J. Exp. Med. 197:1083–1091.
NEW DIGS  The IBCB, like many Chinese institutions, has a new building.
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The results were striking. In 1999, researchers at IBCB’s two 
predecessors published 284 papers, but only 85 in journals listed on 
the Science Citation Index (SCI)—the rest were in Chinese 
language  journals.  In  2001,  IBCB  researchers  published  258 
papers, but now 197 were in SCI-listed journals. As Zhu says, 
“That’s quite a big change.” The average impact factor (IF) of IBCB 
publications continues to rise, from 1.8 in 2001 to over 5 in 2006.
Zhu’s students, who share an open of￿  ce space with him, 
choose other high-pro￿  le papers for a weekly journal club. The 
students also research the background and ￿  nd pictures of the 
overseas PI. “When we read papers we only read names,” says 
Zhu, “but at least this way we have some visual knowledge.”
Zhu himself published the ￿  rst paper 
in the Journal of Cell Biology by a team 
based in mainland China (14); the sec-
ond was from Wang Yizheng at neigh-
boring  ION  (15).  The  ￿  rst  Journal  of 
Experimental  Medicine  paper  from 
mainland China also came from IBCB 
(16);  the  senior  author  was  Pei  Gang, 
who is now the director of IBCB’s par-
ent organization.
But more important than any indi-
vidual paper, says Zhu, is that he, Jing, 
and others are working for their coun-
try’s development. “We are making a group effort to do good 
research, and I am only one of them,” says Zhu. “The most 
important thing is [that] each of us becomes stronger so all of 
CAS and all of China becomes stronger.”
￿￿￿￿￿￿￿￿ ￿￿￿ ￿￿￿￿
The success of ION has led to the founding of several other 
institutes. Like ION, they have directors with extensive hiring 
and ￿  ring power, but unlike ION they are focused on trans  lational 
or medical research.
The Institute of Health Sciences (IHS) in Shanghai, for 
example, opened in 2002 as a joint venture between CAS and 
Shanghai Jiaotong University School of Medicine. It covers a 
wide range of basic, clinical, and translational research, and is 
run by Zang Jingwu, who left his professorship at Baylor 
College of Medicine (Houston, TX) to become IHS director.
A newer venture is the Institute of Molecular Medicine (IMM; 
at Beijing University), which is focused on cardiovascular research. 
It was founded in 2004, with Xiao Rui-Ping as the director.
For many years, Xiao and her husband Cheng Heping shuttled 
between Beijing and their full-time, tenured jobs at the National 
Institutes of Health (NIH; Bethesda, MD). Finally, says Cheng, 
it was time to commit. “There is opportunity here,” he says. “I 
needed to come back and push with both hands, not with one 
hand.” He resigned from the NIH in early 2006.
His gradual commitment is part of a common pattern. Many 
overseas Chinese academics initially commit only to part-time 
involvement in China. But, says Cheng, “that phase is almost 
over. In that transition period, even if you came for a seminar 
it helped, then if you came for a while it helped.” Now, al-
though Cheng says the visitors are still useful “for connec-
tions,” their involvement has become increasingly controver-
sial (17), and the real demand is for full-time staff. “For our 
recruitment, we usually give a couple of years for the transi-
tion,” he says.
Once in China, says Cheng, “you do the same work, but you 
make a greater difference here. Through me, the students can get 
closer to the frontier.” There is also the challenge of creation—
whether it is the hiring of faculty or the building of animal 
facilities. “At the NIH, everything is predictable,” he says. “Here, 
you have to build the road when you move forward. It’s exciting, 
but you need to work twice as hard.”
IMM currently has six faculty. “With Mu-ming [Poo at ION], 
Pei Gang oversees 
Shanghai’s CAS 
biology institutes.
From isolation to leadership
When Jing Naihe arrived in 1982 to do his Ph.D. at the 
CAS Institute of Biochemistry in Shanghai, it had a history 
of huge teams where “two or three were the brains, and 
the rest were the hands. But when you [eventually] had to 
do individual research you didn’t know how to do it.” 
Although group size had shrunk by the time he joined, 
Jing was still isolated from international science. “I never 
read Nature, never read Science, never read Cell,” he 
says. “It was not my business.”
Jing had no money to buy imported chemicals, so 
he spent three years making them. Only then could he 
get started on peptide synthesis.
In 1989, he had a chance for his ﬁ  rst overseas 
stint—a neuroscience postdoc in Japan—via an exchange 
program. “Neuro  peptides 
seemed very interesting,” 
he says. “But what is 
neuroscience—I didn’t 
know. The ﬁ  rst year was 
very hard.”
His two-year stay in 
Japan coincided with the 
1989 Tiananmen Square 
protests and crackdown. 
In response to Tiananmen, 
the US eased visa and 
permanent residence 
restrictions for Chinese 
nationals. Jing had a US visa offer, but for reasons that 
“would take an hour to explain” decided instead to 
return to China. Of the three others in his exchange 
group, two are now in US biotech companies, and the 
other has a position at Harvard Medical School.
Jing has no regrets. At ﬁ  rst, his return to Shanghai 
was marred by impure water that ruined cell cultures and 
sick rabbits that couldn’t make good antibodies. But his 
lab budget has increased 10-fold since 1991, and his 
salary has allowed him to buy a house and afford a car. 
“In 1991,” he says, “I never dreamt of that.”
From isolation to leadership
JING NAIHE★
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he had to recruit who he could, but now it’s a little better,” says 
Cheng. “We had the luxury of predesigning the institute” by hiring 
only those faculty with speci￿  c subspecialties. One of those recruits 
to IMM was Zhou Zhuan, whose previous lab at ION studied 
calcium-evoked secretion (18, 19). “He is the one successful trans-
fer within China,” says Cheng. “Mu-ming should be proud.”
￿￿￿￿￿￿￿￿￿ ￿￿￿￿￿
Like IHS and IMM, the Guangzhou Institute of Biomedicine and 
Health (GIBH) is new and is aimed at translational research. But 
it stands out for another reason. Within one year of its founding, 
GIBH had its ￿  rst 15 PIs. “This is what we call Guangzhou 
speed,” says GIBH deputy director Pei Duanqing.
That speed makes Guangzhou, which is just northwest of 
Hong Kong, part of one of the most extraordinary areas in an 
extraordinary country. Neighboring Shenzhen has grown an 
average of 28% annually in the last 25 years, in the process 
expanding from a ￿  shing village to a city of 12 million.
The growth also explains the presence of GIBH. “Scienti￿  c 
development  lags  behind  economic  development,”  says  Pei. 
“[Closing] this gap requires investment and also a lot of people.”
The Chinese government is now trying to connect researchers, 
thematically  and  geographically,  with  the  frantically  expanding 
economy of the new China. GIBH and a planned proteomics insti-
tute in Pudong (an area of Shanghai recently transformed from 
farmland to international ￿  nance hub) are two signs of this effort.
Bridging the gap between aca-
demia  and  commerce  requires  a 
different kind of research institute, 
says GIBH Director General Chen 
Ling. “We want to combine the best 
of both worlds in this institute,” he 
says. Academic freedom will be backed by the clear goals and 
timelines more characteristic of industry. “If [a PI] has some-
thing promising, the institute will coordinate moving it forwards” 
into development or clinical trials, says Chen.
Chen got his Ph.D. from Indiana University; he had been ad-
mitted as part of the fourth class of CUSBEA students. Later, at 
Merck, he helped develop an HIV vaccine that is currently the 
most advanced in clinical trials; he then moved on to the mouse 
knockout company Lexicon Genetics.
He arrived at GIBH in 2004 and by the end of April had only 
3 colleagues, including a driver and an accountant. Two years 
later, there are 18 PIs, 220 staff, and 100 graduate students. The 
aim by 2009 is to have 30 PIs, with a ￿  nal count of 400–500 staff 
and 500 students. Most of the PIs have signi￿  cant experience in 
industry,  including  large  companies  such  as  Bristol-Myers 
Squibb, Amgen,  and  Wyeth,  giving  GIBH  a  more  explicitly 
commercial emphasis than IMM and IHS.
Next comes the real challenge of producing results. “There is 
no single criterion” for success, says Chen, although it will 
include a mix of successful recruitment of PIs, education of 
Moving ahead
Once  Zhang  Yonglian  entered  her  six-
ties, her career really got going. She had 
been based at the Shanghai Institute of 
Biochemistry (the precursor to the Institute 
of Biochemistry and Cell Biology [IBCB]) 
since 1957. But it was not until 2001, 
ten  days  after  her  66th  birthday,  that 
she  published  three  very  signiﬁ  cant 
pages. Those pages were the ﬁ  rst Science 
paper  from  her  institute  and  only  the 
third  Science 
paper in biology 
for  all  of  main-
land China.
Zhang  had 
not been idle be-
fore 2001. After 
the Cultural Revo-
lution she got her 
Ph.D.,  a  degree 
that was not offered under the previous 
Soviet-style  system.  Then,  in  1983,  she 
began two years of work at the Imperial 
Cancer Research Fund in London, UK. Sub-
sequent work in Shanghai was punctuated 
by research stints back in the UK and in the 
US and Australia.
Chinese awards came for her work 
on androgen regulation of gene transcrip-
tion, but it was a switch to a study of the 
epididymis that was crucial. She chose the 
subject matter for reasons of national need: 
population control was the topic of the day, 
and the epididymis is the conduit that 
directs sperm maturation. As the maturing 
sperm travel, they encounter ﬁ  rst proteins 
that  stimulate  motility,  and  later  proteins 
that boost their survival and resistance.
The result, says Zhang, is “beginning 
and end regions that are more different 
from each other than heart compared with 
eye.” Subtractive hybridization has given 
her a host of differentially expressed genes 
whose products are expressed on or bind 
to different parts of maturing sperm cells. 
Following up on those proteins continues 
to keep her busy. Zhang got the “model 
worker  of  China”  award  in  2003  and 
shows no signs of slowing down.
The Science paper was based on 
Bin1b, one of the differentially expressed 
proteins. Zhang found that this epididy-
mal protein not only looks like but also 
acts as an antimicrobial β-defensin pep-
tide  (1).  Leukocytes  can’t  get  into  the 
epididymis, and Bin1b was the ﬁ  rst clue 
about  how  the  male  reproductive  tract 
protected  itself  from  the  outside  world. 
Zhang later helped show that Bin1b also 
turns on sperm motility (2).
Submitting to Science seemed reason-
able, said Zhang, because a paper about 
an epithelial defensin had been in the jour-
nal in 1995. “And our paper,” says Zhang 
with a cheeky smile, “was more interest-
ing.” It went through the review process at 
Science quickly. With eyes moistening, she 
explains how she was “deeply moved” by 
the  editing  help  that  the  staff  at  Science 
gave her. And the acceptance, says Zhang, 
“was like a dream.”
1.  Li, P., et al. 2001. Science. 
291:1783–1785.
2.  Zhou, C.X., et al. 2004. Nat. Cell Biol. 
6:458–464.
ZHANG YONGLIAN
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GIBH brings 
science to 
a booming 
economy.★
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The general
One fringe beneﬁ  t of employment at 
the Second Military Medical University 
(SMMU)  in  Shanghai  is  a  military 
rank. For Cao Xuetao, that makes him 
not only a professor, director of the 
Institute  of  Immunology,  and  vice 
president of the university, but also a 
general. It is a rank that carries over, 
in a less ofﬁ  cial capacity, to the world 
of Chinese immunology.
Cao is a member of a key MOST 
committee and thus has intimate knowledge of, and involvement 
in, funding decisions. Only a select number of other bioscientists 
have his kind of broad political inﬂ  uence.
In part, this inﬂ  uence stems from his remarkable, made-only-
in-China story. Born in 1964 to two professor parents, his entire 
education and career has been based at SMMU. He had an 
M.D. by age 22, a Ph.D. by 26, and a full professorship by 28, 
and then was appointed chairman of the Department of Immunol-
ogy by 31, and director of the Institute of Immunology by 35. He 
is now president of the Chinese Society for Immunology.
His ailing supervisor retired in the second year of Cao’s 
Ph.D., but he asked Cao to turn down a postdoc offer from 
Charles Janeway in 1991 so that Cao could keep the lab open 
in China. Since then, Cao has made short visits to labs in many 
countries. But his lack of long-term overseas experience, he 
says, “is very unique in the current [Chinese] system.”
It has also been an opportunity. “Although I’m young, I’ve 
had the chance to attend the important national meetings and be 
part of national bodies to develop science, to evaluate grants, 
and to determine the funding,” he says.
Cao’s methods for building a local power base have been 
entrepreneurial and far from conventional. It started with Cao 
signing over rights for the production of various recombinant 
cytokines to a company in Shanghai. “I used the money I earned 
to establish this building,” he says. “This whole building”—a ﬁ  ve-
story institute within SMMU—“is my lab, designed by me, 
together with my colleagues and the architects.”
He moved into the building in 1999. The current staff 
includes 12 Ph.D. students, 6 Master’s students, 2 postdocs, and 
14 technicians, but also 18 other staff (lecturers, associate 
professors, and research assistants). The Institute therefore resem-
bles a multitiered German lab more than the independent labs 
being set up by young PIs returning to China from the US.
A large lab is necessary, Cao says, because the Institute 
is self-sufﬁ  cient and does not draw upon central facilities else-
where in SMMU. “If we have 50 people in my lab,” he says, 
“it is equivalent to 20 people in the US.”
The large-scale science extends outside of SMMU. Cao 
coordinates a national program in immunology research that 
covers almost 20 labs; its mandate starts again in 2007. This 
is the kind of structure favored by MOST. The NFSC, which is 
the funding body preferred by many individual PIs, “uses a 
very efﬁ  cient and equal evaluation method,” admits Cao. “But 
this is for individuals not teams. It we want to do teamwork, 
especially uniting several great labs, the NSFC has no ability 
to coordinate it. MOST has the ability to coordinate it.”
Cao’s own research is focused on dendritic cells (DCs) and 
various aspects of immune regulation. In the last three years, he 
has published 1 paper in Immunity (1), 10 papers in Blood, and 
he recently found that splenic stroma spurs mature DCs to differ-
entiate into regulatory DCs (2). A DC-based vaccine that he 
helped develop is in a phase II trial for advanced cancer.
The next challenge is to build capacity in immunology 
outside of SMMU. China’s “background is very weak in im-
munology,” says Cao, although he says returnees such as Zang 
Jingwu at the CAS Institute of Health Sciences in Shanghai 
have helped improve the situation. In addition, he hopes his 
own domestic career can show others that “you have a chance,” 
even without overseas experience. The opportunity is there, he 
says, “but you have to communicate with the ofﬁ  cials of the 
government to get their funding, to get their support.”
1.  An, H., et al. 2006. Immunity. 25:919–928.
2.  Zhang, M., et al. 2004. Nat. Immunol. 5:1124–1133.
Cao Xuetao used his 
own funds to build his 
immunology institute in 
Shanghai.
A painful funding increase
Two rather sad seedlings are perched on Bao Lan’s filing cabinet. 
Her son is conducting an early science experiment. Plants, it 
turns out, do poorly if they have either only earth or only water.
These days Bao’s lab at the Institute of 
Biochemistry and Cell Biology (IBCB) is well 
equipped, but 10 years ago her department in 
Xi’An, in western China, looked more like her 
son’s plant experiment. After getting an initial 
grant of only 30,000 RMB (less than US$4,000), 
“I immediately spent 10,000 of that on a 
computer to write the next grant,” she says. 
The money was so sparse that her husband, 
Zhang Xu (now at the CAS Institute of 
Neuroscience [ION] in Shanghai), would go back to Sweden every 
year to do experiments at the Karolinska Institute.
As the funding picked up, Bao and Zhang discovered an 
unusual pathway: an opioid receptor that was sent to the 
plasma membrane not by constitutive but rather by a 
regulated, inducible pathway (1). They later found that the 
induction was via binding of pain neuropeptides to the receptor 
(2). Zhang continues to research pain conditions, but Bao is 
now focusing on Na
+ channel trafficking, which is modulated 
by nerve injury and inflammation.
1.  Bao, L., et al. 2003. Neuron. 37:121–133.
2.  Guan, J.S., et al. 2005. Cell. 122:619–631.
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students, publishing of papers, and registering and 
licensing of intellectual property.
GIBH was funded by a start-up grant of US$36 
million, with equal shares coming from CAS, the prov-
ince of Guangdong, and the city of Guangzhou. “The 
stakeholders put up this much money, so they have a 
right to demand an outcome,” says Pei.
But in an area accustomed to building factories and 
getting quick results, the slower speed of drug develop-
ment will take some adjustment. Developing a drug in the US is 
estimated to take 10–15 years and cost US$800 million; GIBH 
has far less money and time. “It has been my job to communicate 
the differences and the gap we perceive, and so far they have 
been very receptive,” says Pei. “They have become more realis-
tic and have been very supportive of the direction and progress 
we are making.”
Chen is not without his doubts. “I don’t know if China is 
truly ready for this,” he says. “It still takes time and effort to 
optimize the research conditions. But if we don’t come to push it 
now it won’t get better.”
As  they  move  into  commercial  research,  Guangzhou  and 
China may initially make use of their built-in advantages, such 
as cheap and plentiful sources of nonhuman primates and low 
labor costs for mouse facilities. But “over time,” says Chen, 
“China is so big that it can do everything.”
￿￿￿￿￿ ￿￿￿￿￿￿ ￿￿￿￿ ￿￿ ￿￿￿￿￿
If ION was a break from the old CAS culture, then Beijing’s 
National Institute of Biological Sciences (NIBS), led by Xia-
odong Wang and Xingwang Deng, is a complete rupture. Wang 
is a long-time recipient of the Howard Hughes Medical Institute’s 
(HHMI) largesse. Now, he and Deng have brought that con-
cept—of supporting individuals rather than speci￿  c projects—
and convinced the Chinese government to bankroll an audacious 
center of excellence.
NIBS has its critics, who feel it is too elitist and soaks up too 
much money, and the resentment has led to dif￿  culties in estab-
lishing collaborations with other Chinese scientists. But Wang is 
unapologetic about the money. “I think it’s the only way you get 
on the fast track: you create a place that will be competitive on 
an international level,” he says. “If you want a scientist that has 
international market value, you have to pay them accordingly. 
You can certainly justify these salaries by merit.”
Salaries at NIBS are US$50-60,000 for an assistant investiga-
tor—10–15 times the income of an average Beijing resident, and 
almost three times what starting PIs at most other Chinese insti-
tutions get. Without having to write an external grant applica-
tion, each NIBS junior PI also gets 3 million RMB for the ￿  rst 
year and 2 million RMB for each of the subsequent four years, 
for a total of ∙US$1.4 million over ￿  ve years.
For a normal lab in China, “this money is enough for at least 
20 people,” says Shao Feng, a PI at NIBS. Typical costs in China 
are ∙US$5,000 for a technician, ∙US$6,000 for a postdoc, and 
∙US$2,000 for a student, although NIBS tends to pay more.
Other costs are also lower. “I have close to 4,000 mice here,” 
says NIBS cloning researcher Gao Shaorong. “You can imagine 
in the US how much I would pay for that.”
Pluripotent energy
Some  researchers  take  an  hour  to  explain  a  single 
project. Jin Ying at Shanghai’s IHS gets through half a 
dozen, plus a few phone calls, within less than 20 
minutes. With all the spinning toward her audience to 
address each new topic, an inevitable byproduct is some 
spectacular ﬂ  y-away hair. Jin is a woman in a hurry.
Her projects are focused on understanding the 
pluripotency of embryonic stem (ES) cells and how 
self-renewal  is  regulated. 
Starting  from  the  key  tran-
scription factor Oct4, she is 
purifying associated proteins 
and identifying target genes. 
One interacting factor ubiq-
uitinates  and  inactivates 
Oct4 (1) and in turn binds 
proteins linked to chromatin 
remodeling  and  apoptosis. 
Jin also used chromatin im-
munoprecipitation to identify a factor that seems to 
drive endodermal differentiation. These functions can 
now be tested with the siRNA system that Jin has 
perfected for use in mouse ES cells.
Jin is also codirector of the Key Lab of Stem Cell 
Biology, a consortium made up of IHS and IBCB faculty. 
This is one of several groups that are making China a 
leading center for stem cell research (2).
1.  Xu, H.M., et al. 2004. J. Biol. Chem. 
279:23495–23503.
2.  Normile, D., and C.C. Mann. 2005. Science. 
307:660–664.
GIBH is based in booming Guangdong province.
GIBH Deputy Director Pei Duanqing (left) 
and Director General Chen Ling (right).
JIN YING
Pluripotent energy★
THE RETURNING TIDE | The Journal of Experimental Medicine  225
Any equipment costing more than US$10,000 is paid for by 
NIBS, not out of the PI’s general budget, and special requests 
for more funds can be made to Wang and Deng. Applications 
for outside funding are allowed but not encouraged; few have 
taken this route so far.
Wang is based at the Uni-
versity of Texas Southwestern 
Medical Center (Dallas, TX) 
and,  like  Poo  at  ION,  does 
not draw a salary from China. 
“That makes my job a little 
easier,” he says. As a volun-
teer, Wang is unlikely to be 
criticized for being part-time 
or for lobbying for high sala-
ries for others.
Deng  (Yale  University, 
New  Haven,  CT)  was  the 
￿  rst  to  contact  his  friend 
Wang about running NIBS. 
Wang considered quitting HHMI and Texas to move to NIBS, 
but decided that this would compromise his current research, 
which requires signi￿  cant manpower in chemical synthesis. In 
April 2003 he did, however, sign up for the directorship. His 
involvement was a key factor for many subsequent hires. The 
Chinese  government  has  been  known  to  change  its  mind 
abruptly, but with Wang on board, said one PI, “I know he’s 
really going to do it.”
The NIH’s Lu says that the Chinese government needs to do 
whatever is necessary to get more leaders like Wang. “First-class 
people  recruit  ￿  rst-class  people,”  he  says,  “but  second-class 
people  recruit  third-class  people,”  because  they  are  insecure 
about competition.
NIBS was built in a new industrial park north of Beijing. Insects 
still invade the labs as a reminder of the area’s swampy past, and the 
staff and students rely on shuttle buses for transport to the isolated 
site. A subway extension to the park has been promised, however, 
and a 3,000-bed hospital will be one of the park’s new tenants and 
hopefully a source of collaborators with NIBS researchers.
The ￿  rst PI to arrive at NIBS full-
time was Guo Yan in January 2004. “It 
was really scary,” he says. “The build-
ing was totally empty. I spent almost 
one year just ordering machines.”
Three years later, it is a very dif-
ferent  scene.  In  addition  to  the 
outpost labs of the three US-based 
PIs (Wang, Deng, and Yi Rao), there are now 15 full-time PIs 
at NIBS. Meals at the cafeteria must run in shifts.
The PIs are a very young group. “By default, most people are 
young, fresh out of postdocs,” says Wang. For now, “it’s impos-
sible to get established people here. As time goes on, with turn-
over, it will become like other places.”
Of￿  cially, recruitment has been competitive. Most of the PIs, 
however, have worked with a US-based Chinese PI, who either 
recommended them or twisted their arm to convince them of 
NIBS’s potential. Whatever the method for recruitment, the re-
sults are impressive. The one senior and 14 junior PIs at NIBS 
had, for example, a total of 15 Cell, Science, and Nature ￿  rst 
authorships upon their arrival; two had turned down offers from 
Duke and Harvard Universities. NIBS is currently limited to 
25–30 PIs, and recruitment is only likely to get more selective.
Inventive pathogens
For Shao Feng at NIBS, it’s all about keeping things 
interesting. “For a biochemistry lab you need to be 
constantly creative to come up with new things,” he says. 
“That’s the way I like to do science.”
Luckily for Shao, he studies pathogens, and patho-
gens do many bizarre things to their hosts. Shao found 
that a Yersinia protein cleaves the host cell’s Rho to re-
lease it from the membrane (1). A similar Pseudomonas 
protein cleaves a kinase in plants, and it is the cleavage 
not the invading protein that is detected by a plant 
resistance protein (2).
Now,  he  is  on  the  trail  of  proteins  from  two 
bacterial pathogens: one that uses “a completely new 
enzymatic reaction” to chop out a protein modiﬁ  ca-
tion  (3);  and  another  that 
causes cells to halt at an unu-
sual cell cycle arrest.
The  projects  have  kept 
multiplying as he has expand-
ed to a lab of 12 within 18 
months. “For a lot of jobs you 
are constantly repeating,” he 
says, “but here you are con-
stantly reinventing.”
1.  Shao, F., et al. 2002. Cell. 109:575–588.
2.  Shao, F., et al. 2003. Science. 301:1230–1233.
3.  Li, H., et al. 2007. Science. In press.
SHAO FENG
Xiaodong Wang has brought the 
Howard Hughes model to NIBS 
in Beijing.
CHEAP LABOR  Plenty of willing workers translates into cheaper labor 
costs in Chinese laboratories.
NIBS 
supports 
individuals 
rather than 
projects.
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Feeding the masses
“In China ‘food safety’ doesn’t mean what it means 
in the US,” says NIBS researcher Guo Yan. Rather 
than worries about transgenic food, “in China food 
safety is whether we have enough food to feed the 
Chinese people.”
Plant breeders and researchers did not go home when 
the Green Revolution was declared a success; they 
continued to get almost half of the money in Chinese 
biological research. Much of this money goes to traditional 
breeding efforts, but plant researchers such as Guo are a 
strong presence amongst the recent batch of basic science returnees.
Guo works on salt stress and drought response in Arabidopsis. “If I can 
really do something in [applied research] I would choose this first, but so far 
I have chosen to do basic research,” he says. “The more you work in this field, 
the more you think it is hard. If this is possible, God should have done it 
already. We need to understand it more before we can help.”
The one complaint from the NIBS PIs is a lack of international 
visibility, leading to skepticism from reviewers of NIBS manu-
scripts. Not only is NIBS new, but so are the PIs. Many of them 
came directly to NIBS, thus missing out on the self-advertisement 
that goes along with being on the US or European job circuit.
NIBS  is,  above  all,  an  experiment  in  funding.  But  will 
China rely elsewhere on the NIBS/HHMI-style funding of the 
individual rather than the project and build more NIBS-style 
institutes? “Yi Rao says we can have 10 of them,” says Poo. 
“I doubt it.” Even NIBS supporters talk of the institution as a 
“catalyst” for cultural change rather than a funding template 
for all of China. “China has a vast network [of research insti-
tutions] already,” says Princeton’s Shi. “How to make those 
institutes better is the primary challenge.”
Deputy Director Zhi Gang says NIBS will also be important 
in that process. “This institute is in China, so it is surrounded by 
traditional behavior,” he says. “You have to break up this envi-
ronment for the new system to work.” The stakes are high. With 
possibilities for expanding or replicating NIBS, or exporting its 
faculty and the NIBS culture to other sites, success at NIBS 
could have far-reaching consequences for Chinese bioscience.
￿￿￿￿￿￿￿￿ ￿￿￿ ￿￿￿￿ ￿￿￿￿￿￿￿￿￿￿
The  future  of  Chinese  science  revolves  around  three  main 
challenges: improving the education system for graduate stu-
dents; forging a connection between scientists and the general 
public; and constructing a funding system suited to the coun-
try’s unique needs. If these three issues are solved, getting 
more returnees should not be a problem.
Although  the  research  environment 
continues to improve, the ￿  x is often slowest 
for students. “Teaching is a major problem 
facing Chinese graduate training,” says Shi. 
“If students don’t have good teaching, they 
won’t develop critical thinking.”
Teaching  in  China  is  complicated  by  a 
deeply ingrained respect for seniority in gen-
eral  and  teachers  in  particular.  Poo  has 
blamed “the confucian tradition of respecting 
customs and hierarchy” and “deference to 
authority and to existing paradigms” (20) 
for sti￿  ing creativity and producing a stale 
teaching  dynamic. According  to  Lu:  “It’s 
not fostering creativity and innovation; it’s 
old-fashioned knowledge-based education.”
“In  China,  the  professor  talks  and  the 
students take notes,” says Jian Li of Harvard 
Medical School (Boston, MA), who teaches 
at the IMM at Beijing University. “I try to use 
GUO YAN
Feeding the masses
GROWING FAST  NIBS has rapidly built its staff into the hundreds.★
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Structured energy
Chai Jijie has a whole lot of energy and is in 
a  whole  lot  of  hurry.  In  addition  to  reading 
papers, supervising his lab, and handling ad-
ministration, “I spend a 
lot of time in the lab—
at  least  12  hours  a 
day,” he says. “I’m kind 
of a crazy scientist.”
That energy yield-
ed him six ﬁ  rst (or coﬁ  rst) 
author  papers—includ-
ing two in Cell and two 
in  Nature  (1–4)—dur-
ing his stay in Yigong Shi’s lab at Princeton. And 
yet he applied for only one US-based job (at the 
drug company Pharmacia). “I’m not good at look-
ing for a job,” admits Chai.
Luckily, Shi is on the NIBS recruitment com-
mittee, so Chai ended up in Beijing. He couldn’t 
be  happier.  “With  the  money  we  get  we  can 
work on almost anything we want,” he says. “Es-
pecially for a new lab, that is really good—we 
can work in two or three ﬁ  elds and then end up 
focusing on the one that really works.”
Already Chai has branched out successfully 
from his postdoctoral work with Shi on the structure 
of  apoptosis  proteins  (1–5).  He  has  determined 
how a protein called WDR5 recognizes K4-methyl-
ated histone H3 (6), and how an auxiliary subunit 
of the voltage-gated potassium channel clamps the 
main channel together and modulates its gating 
(7). A submitted paper explains how a bacterial 
protein targets its plant host, and plenty of other 
projects are at earlier stages.
Driving  it  all  is  a  simple  enthusiasm. 
“Sometimes science is just like a game,” says 
Chai. At the end of the chase, “I can be the ﬁ  rst 
one in the world to know something that other 
people don’t know.”
1.  Chai, J., et al. 2000. Nature. 406:855–862.
2.  Wu, G., et al. 2000. Nature. 408:1008–1012.
3.  Chai, J., et al. 2001. Cell. 104:769–780.
4.  Chai, J., et al. 2001. Cell. 107:399–407.
5.  Chai, J., et al. 2003. Nat. Struct. Biol. 
10:892–898.
6.  Han, Z., et al. 2006. Mol. Cell. 22:137–144.
7.  Wang, H., et al. 2006. Nat. Neurosci. 
doi:10.1038/nn1822.
the model of when I took classes in the US, and bring back 
discussion.” Without such discussion classes, says Carnegie’s 
Zheng, “I don’t think enough emphasis is being put on placing 
research in a bigger context. The later year students are still 
struggling with that.”
Yi Rao responded by creating Bio2000, a full-year course 
on molecular and cell biology originally given in Shanghai 
and  now  expanded  to  Tsinghua  and  Beijing  Universities. 
Guest lecturers spend one week on a topic in both Beijing and 
Shanghai. But “we cannot take over the job of teaching,” says 
Shi. “It is up to the institutions.”
Some of those institutions currently struggle. Returnees who 
only did postdocs overseas were never exposed to the discus-
sion-based courses common in US Ph.D. programs; they are also 
under immense pressure to publish as soon and as much as pos-
sible, so teaching is not high on their agenda.
CAS institutes have traditionally focused on research, not 
teaching, so some deputize universities to do the teaching for 
them. The resulting classes may be very disconnected from 
the students’ research. This kind of treatment of CAS students 
makes at least one Beijing University student happier to be in 
CHAI JIJIE
WANG XIAOCHEN
227
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5.  Chai, J., et al. 2003. Nat. Struct. Biol.
10:892–898.
6.  Han, Z., et al. 2006. Mol. Cell. 22:137–144.
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Structured energy
Not a candidate for engulfment
NIBS  is  competitive.  Engulfment  research  is  com-
petitive.  And  Wang  Xiaochen,  despite  her  mild 
manner, is ready for both.
Wang studied general apoptotic mechanisms 
in worms (1) before moving on to her current inter-
est: engulfment of dying cells. Mammalian studies 
had suggested that phosphatidylserine (PS) acted 
as an “eat-me” signal on dying cells; Wang identi-
ﬁ  ed the worm PS receptor and the pathway that it 
activated (2).
The weak phenotype from loss of the PS path-
way in worms has inspired Wang to do an enhancer screen. 
She is also doing an RNAi screen for engulfment defects, as the 
existing engulfment mutants all come from cell death screens. 
Even the products of those earlier mutants pose plenty of ques-
tions: CED-1 is a receptor without a known ligand; and CED-7 
is a transporter without a known cargo.
At NIBS, Wang has the ability to follow up all these ideas, 
and that made the decision to come an easy one. “The offer 
here was everything I was looking for,” she says. “The most 
important thing is there is enough funding so you don’t spend 
80% of your time writing grants. And there are enough stu-
dents. And a good research environment—a really good group 
of people. In the US there are a lot of good choices but the 
funding situation is very tough.”
The trade-off is the pressure. “The idea of this institute is to 
go to another level, to make the whole scientiﬁ  c work effort in 
China go to another level,” she says. “You need to be really 
good to survive here.”
1.  Wang, X., et al. 2002. Science. 298:1587–1592.
2.  Wang, X., et al. 2003. Science. 302:1563–1566.★
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Animal Farm
Liu Shusen was determined that banish-
ment to a pig farm in 1969 was not go-
ing to be the end of his scientiﬁ  c career. 
Liu, like most Chinese academics during 
the Cultural Revolution, was sent from 
his research institute to pay his dues in 
the  countryside.  Initially,  his  research 
background counted for nothing.
But Liu’s scientiﬁ  c mind was still at 
work. He ﬁ  gured out that the villagers’ 
pigs  were  getting  sick  because  they 
were eating cottonseed. Chemical anal-
ysis in a lab in Wuhan revealed that the 
toxic culprit might be a chemical called 
gossypol.  Boiling  the  cottonseed  de-
stroyed its toxicity while preserving the 
cottonseed’s  nutritional  value  for  the 
pigs. To Liu’s relief, the villagers realized 
that a scientist could in fact be useful.
Once  his  reeducation  year  was 
up, but well before the end of the Cul-
tural Revolution, Liu was put back into 
research—his  expertise  in 
membrane  biology  ﬁ  tted 
Mao’s interest in the origin 
of life. (A sustained nation-
al interest in science did not 
reemerge,  however,  until 
Deng  Xiaoping  took  over 
after Mao’s death in 1976.) 
Since 1971, Liu has worked 
at the CAS Institute of Zool-
ogy in Beijing, focusing on 
the  biochemistry  of  mito-
chondrial bioenergetics.
Liu’s former student, Chen Quan, 
is at ﬁ  rst glance a very different scien-
tist.  Chen  has  research  experience  in 
Europe and the US, and is a card-carry-
ing cell biologist. He has recently found 
that a fusion protein works only when its 
motility domain can help to drive two 
mitochondrial membranes together.
But, in a strange twist of fate, Chen 
and Liu’s careers recently circled back to 
meet one another. In the countryside, Liu 
had  found  that  gossypol  in  cottonseed 
makes pigs sick. Now, Chen has reported 
that gossypol induces a conformational 
change in Bcl-2 to induce apoptotic cell 
death (1). Luckily for Liu, he didn’t need to 
know that level of detail 35 years ago to 
save both the pigs and his career.
1.  Lei, X., et al. 2006. FASEB J. 
20:2147–2159.
a university setting. “Here, we are students,” he said. “At the 
institutes, they are like workers.”
But the institutes that have changed the most for PIs have also 
changed the most for students. “In my lab I encourage [students] 
to challenge me,” says Shao at NIBS. “In this institute we are 
trying to change the culture.”
Because NIBS is so young, most of its teaching is still done 
by universities. As more PIs arrive, however, in-house courses 
are being developed.
At ION, the process is further along. Compared with most 
other Chinese institutions, students are noticeably more willing 
to speak up and “much more active,” says Rao. “They are lead-
ing the pack, and it affects the other institutes in China.” ION 
achieved this, he says, “by having visitors and PIs encourage 
them and not treat them like slaves.”
￿￿￿￿￿￿￿ ￿￿ ￿￿￿￿￿￿￿
Perhaps the most nebulous challenge facing Chinese scientists is 
to build understanding and support for basic research amongst 
the general population. “Science as a discipline to seek knowl-
edge for the sake of knowledge, I don’t think that has roots in 
China,” says Xiaodong Wang. “That’s probably the basis for the 
problems [such as funding disputes]. I think if society treats that 
as a novel goal, things will be easier.”
Unfortunately, as Poo has pointed out (21), science and 
technology are uni￿  ed not only in the name of the Ministry of 
Science and Technology but also in the single word “keji.” True 
innovation, a stated aim of the Chinese government, will be 
challenging if science is seen only as an engineering project (21).
Even some scientists have doubts about throwing so much 
money at science in what is still a developing country. Beijing 
University’s Wang Shiqiang thinks basic education for the gen-
eral population is more important. “For at least 20 years, I think 
the science should be secondary,” he says. “China does not need 
such a large scienti￿  c team; they should shrink the team but 
make sure the ones in the team have suf￿  cient support.”
Rather than support science for science’s sake, politicians 
have allotted money because science promises to contribute to 
national growth. That creates a dangerous situation for researchers. 
“The society is still young, and there is an in￿  ated expectation 
that one day you discover and next day you have a cure,” says the 
NIH’s Lu. “You have to gradually educate the public that science 
takes time and needs support.”
At least in some universities, the embrace of scienti￿  c advance-
ment as a national goal is having positive effects, as support staff 
have fallen into step. “In the past, they didn’t have much idea that 
the administration should service science; we had to ￿  ght for a lot 
of stuff,” says Zhang Bo of Beijing University. “Now, it is much 
easier [for researchers] to concentrate on the science.”
￿￿￿￿￿￿￿ ￿￿￿￿
Money, or at least the total amount of money available, does not 
seem to be the limiting factor for Chinese bioscientists. The 
Chinese government has tripled the amount of its research and 
development funding in the last 10 years; it projects a further 
fourfold increase in the country’s total research and development 
spending from now until 2020. By then, the share of the budget 
enjoyed by basic researchers is projected to triple to reach a 
Chen Quan (left) has inherited both scientiﬁ  c and historical 
lessons from his former supervisor Liu Shusen (right).
Animal Farm★
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Results time
Zhang  Chuanmao  is  in  a 
paper-writing  and  paper-
revising  frenzy.  Four  years 
after returning from a success-
ful  postdoc  in  Scotland,  he 
has accumulated 15 students 
and  2  postdocs  in  his  lab, 
which temporarily slowed his 
publishing record. The picture in one year’s time 
should be very different.
In Scotland, Zhang found that nuclear enve-
lopes would assemble around beads coated with 
Ran (1) or its effector importin-β (2), and that Ran-
GTP  promoted  vesicle  recruitment  whereas  the 
Ran-GTPase cycle promoted vesicle fusion (3).
Once he returned to a professorship at Beijing 
University, Zhang uncovered a series of binding 
relationships leading all the way from the nuclear 
envelope, via importins, to DNA-binding proteins. 
He also has manuscripts detailing how Polo kinase 
regulates microtubule dynamics, and how an un-
usual pole reduplication can cause aneuploidy.
Zhang is extremely sociable, and ﬁ  nds phone 
and email communication with his colleagues out-
side of China frustratingly inadequate. Luckily, he 
says,  the  number  of  collaborators  in  mainland 
China is building steadily.
1.  Zhang, C., and P.R. Clarke. 2000. Science. 
288:1429–1432.
2.  Zhang, C., et al. 2002. Curr. Biol. 12:498–502.
3.  Zhang, C., and P.R. Clarke. 2001. Curr. Biol. 
11:208–212.
level comparable to that in the US.
The results so far are mixed. China had a 20-fold increase in 
publications in international scienti￿  c journals from 1981–2003. 
But the ￿  nal total was just over 5% of the world’s output, and 
much lower in the life sciences: only 2% for plant science and 
0.8% for immunology. Even within that total, some of the publi-
cations come from overseas PIs with part-time appointments in 
China. The quality is also mixed. In 2001, China published only 
1% of the world’s top papers (classi￿  ed in terms of number of 
citations [22]).
It is where the money goes that is the point of contention 
(23). CAS funds researchers at its institutes directly (covering 
approximately half of their needs), but most of the open ap-
plications  from  both  CAS  and  university  researchers  go 
through  two  major  channels:  the  National  Natural  Science 
Foundation of China (NSFC); and the Ministry of Science and 
Technology  (MOST).  MOST  has  more  money  but  has  not 
been winning the popularity contest.
NFSC “has been doing a fabulous job,” says Shi. “It has the 
most rigorous and fair system, and it is enormously popular 
among scientists in China. This already indicates a reform track. 
Agencies like NSFC should be strengthened and given more 
resources over time.”
To  some  extent  this  is  already  happening. The  budget  of 
NFSC has grown by an average of 23% a year since its founding 
in  1986,  albeit  from  paltry  beginnings.  In  2006,  NFSC  had 
US$425 million (still less than 5% of the government’s research 
and development budget), and MOST had US$1.7 billion. By 
comparison, the budget for the US National Institutes of Health 
is close to $28 billion.
The NSFC, modeled on the US National Science Foundation, 
is a standard funding agency dedicated to the natural sciences. 
MOST is a stranger beast. Its critics say it favors large projects 
dictated by politicians rather than scientists (24). Most notable 
Extreme evaluation
During China’s economic rise, millions have plunged from safe 
but meager livelihoods into a far more unstable existence where 
both the risks and potential rewards are high. Ding Mingxiao, 
dean of the College of Life Sciences 
at Beijing University, says the Chinese 
government has asked universities to go 
“step by step,” in contrast to the rapid 
changes at CAS (see main text). But with 
Deng Hongkui, his younger co-PI, Ding has 
found himself very much in risky territory.
Deng was awarded one of 43 Grand 
Challenge grants from the Gates 
Foundation. The grant requires regular 
reporting and yearly milestone 
achievements—a far cry from the university’s usual, more leisurely 
tempo. For the university, says Ding, “this is a large grant from 
outside.” With the accompanying trainings on reporting, patenting, 
and collaboration, “the school can learn a lot.”
The Beijing team is attempting to differentiate human 
embryonic stem (ES) cells into liver or blast stem cells and then 
transfer them to mice. If the resultant mice have humanized livers 
or immune systems, it should be possible to 
infect them with either hepatitis C virus 
(HCV) or HIV, and then use the mice to test 
HCV and HIV vaccines.
Deng is not new to high risk, high 
reward science. Along with several other 
teams, he helped discover that CCR5 was 
a vital HIV coreceptor (1); this followed a 
multiyear hunt in which researchers hit 
many dead ends. Since his return to China 
in 2001, Deng’s focus has been on ES cell 
differentiation, which Chinese researchers have identified as a 
key area for basic discoveries and commercial exploitation.
1.  Deng, H., et al. 1996. Nature. 381:661–666.
DENG HONGKUI
Results time
ZHANG CHUANMAO★
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are the group grants given in priority areas identi￿  ed by the 863 
applied science program and the 973 basic science program. 
Both programs are named after the year (1986 and 1997) and 
month when they started.
Agitation  from  Chinese  PIs  based  overseas  was  aimed  at 
heading off more of these megaprograms, but this appears to 
have been unsuccessful. “The major resources will go to big sci-
ence—it is already decided,” says Poo. “The proteome project 
will  take  hundreds  of  millions  of  dollars.  My  advice,  which 
wasn’t taken, was don’t put money in before recruiting.”
The proteome project is one of the megaprojects announced 
last year in the “National Medium- and Long-Term Programme 
for  Scienti￿  c  and Technological  Development  (2006-20),”  or 
MLP (25). Part economic planning document and part funding 
manifesto, the MLP list of megaprojects was a disappointment to 
those who had been cheered by NSFC’s recent gains.
￿￿￿ ￿￿￿￿￿￿￿￿ ￿￿￿￿ ￿￿￿ ￿￿￿￿￿￿￿
The  debate  between  MOST  and  its  critics  centers  around  two 
themes: a familiar big science versus small science debate; and a 
distinctly Chinese dialogue about how best to promote the country’s 
development. The merits of the anti-MOST arguments from those 
based outside China are generally accepted based on the ￿  rst 
discussion, but then dismissed based on the second.
Poo authored an article in the banned China Voices series that 
was a critique of big science in China (21). “The drive for big 
science in China is really dangerous and unhealthy,” he says. “This 
is the Chinese way of operation—an 
extension of the planned economy.”
China has a history of central or-
ganization and control, but observers 
cite additional reasons for the persis-
tence of megaprojects in the country. 
According to Yi Rao (and many oth-
ers who are less willing to go on the 
record), “ministries argue for self-in-
terest,  not  for  what  is  best  for  the 
country.” MOST resists peer review, 
he says, because it takes away from 
its power. “The prime minister [Wen 
Jiabao] really wants to do something,” 
says Rao, “but he doesn’t know who 
to talk to.”
The large projects promote leadership by the few, and a 
top–down  approach.  Rao  and  colleagues  described  this  as 
“Rule-by-Man” rather than “Rule-by-Merit” in their banned 
Nature article (5). In project selection, they wrote, there are 
“funds leading projects, not projects leading funds.” For refer-
eeing, “one megaproject can include most, if not all, active 
researchers in that area, thereby leaving few or no experts who 
can provide objective and critical evaluation.” Finally, the 
authors dismissed any possible argument for big science: “At 
the present, as in most peace time, there are few well-de￿  ned 
goals that can be solved by a few simple megaprojects.”
Applications for project funds suffer from a lack of scienti￿  c 
scrutiny. “People overemphasize political signi￿  cance,” says Shi. 
“Those applications tend to ￿  y better with those who don’t have a 
background in science, because that is the part they understand.”
Other funders are looking for something tangible: buildings 
and big equipment. As a result, says one researcher, “for the big 
machinery, I would say we have too much money.” In several 
institutes, says Poo, proteomics facilities are already much better 
than those at the University of California, Berkeley (Poo’s home 
base), but lack sound projects that can make full use of them. 
Wastage of these large facilities is a particular risk in a country 
acknowledged to have a shortage of senior scienti￿  c leaders.
The ￿  rst barrier faced by returnees trying to access the money 
is the politics of large group projects. 
MOST money “is only if you are fa-
mous,” says one researcher. “No one 
knows the rules about who gets what 
money.”  Other  researchers  say  that 
“we need to do the social work” to 
get MOST funding, and “the joke is 
that if you want a few million RMB 
you have dinner with someone.”
Evaluation  has  been  another 
problem,  initially  for  all  grants. 
“Grants  were  reviewed  by  your 
friends,” says Lu at NIH. “It is dif￿  -
The NIH’s Bai Lu has helped 
improve grant review.
Big science 
is “an 
extension of 
the planned 
economy,” 
says
 Mu-ming 
Poo.
FEEDING THE BEAST  Demands of growth cast science in a 
technological light.★
THE RETURNING TIDE | The Journal of Experimental Medicine  231
cult for very good science to emerge under those conditions.”
Five years ago, Lu initiated a program for reviewing bigger 
NSFC grants. Leading by example, he and other overseas col-
leagues encouraged critical discussion and con￿  dentiality, both 
of which were previously lacking. Reviewing at MOST, however, 
has not seen similar improvements.
Publications are a major criterion for success. This was 
initially welcomed in China as a sign that merit-based evalua-
tion  had  arrived,  but  some  now 
feel the emphasis is suffocating. 
“The  evaluation  committee  is 
generalist, so they just look where 
you  published  your  paper,”  says 
one researcher. “If you do science 
[just]  for  publications,”  he  says, 
“you are not a scientist.” Accord-
ing  to  Carnegie’s  Zheng:  “The 
biggest  thing  that  is  absent  [in 
China]  is  evaluating  progress 
rather than just the impact factors 
of papers published.”
Some of the problems with lim-
ited reviewing panels may decrease 
over  time.  “The  Chinese  scienti￿  c 
community is small,” says Xiaodong 
Wang. “They are the ones that get 
called for everything, and that gener-
ates the political problems. With the 
number of good scientists expand-
ing, this problem will become less 
and less.” Similar issues are arising 
with regulatory bodies, where cur-
rently the regulators and the regulat-
ed sometimes overlap (26).
￿￿ ￿￿ ￿￿￿ ￿￿ ￿￿￿￿
The arguments countering the ex-
patriates are based on two grounds: 
that most of the science isn’t really 
big; and that, when it is, it is needed 
to build the country.
“I  don’t  think  that  big  science 
dominates  in  China,”  says  CAS’s 
Chen Zhu. “If you do a more careful 
analysis of the funding of biological 
science in China, then the funding 
for proteomics and genomics is just 
15-20%. The small projects are still 
the mainstream in China.”
Chen, like many other academ-
ics high up in the decision-making 
tree,  actually  professes  support 
for unplanned, basic science. “It is 
dif￿  cult  to  plan  real  science,”  he 
acknowledges. “You can plan some 
engineering projects; you can plan 
some  infrastructure  projects;  you 
can even plan some areas of priority in science. But you cannot 
plan where the breakthroughs will come in science.” As a result, 
he says, the MLP strategy “will be evolving over time.”
Chen does, however, see the need for projects such as the 
proteomics center. “These are not research projects but infra-
structure,” he says.
Part of the argument centers on a willingness to play the game. 
Politicians, says Poo, “think [that] in a socialist country you can 
Big science methods; small science thinking
Finding nuggets of information in huge piles of data is He Dacheng’s specialty. 
It starts in his ofﬁ  ce—with its cascading mountains of newspapers, reprints, 
and the odd dissecting scope and can of dried milk—and extends to his work 
as one of the pioneers of proteomics in China.
The heavy emphasis on proteomics in China was a question of timing. 
The Chinese government was very attracted to the orderly achievability of the 
Human Genome Project, but the country’s development came too late for it to 
make any more than a minor contribution to that project. That left a gap that, 
partly  at  He’s  suggestion,  was  ﬁ  lled  by  proteomics.  He 
helped form the Universities’ Confederated Institute for Pro-
teomics (UCIP) in 2001 and became its chief scientist.
Proteomics in China has been criticized because of 
the tendency to focus on big science projects such as the 
identiﬁ  cation of all proteins in the liver. He says that pro-
teomics  must  initially  focus  on  big  science  projects  that 
identify many proteins. Some of these projects are receiv-
ing tens or hundreds of millions of dollars, under the leader-
ship of people such as Rao Zihe (see main text) and He 
Fuchu (Institute of Radiation Medicine, Beijing).
But as it matures, says He Dacheng, proteomics “can 
and ought to be under the guidance of real biological ques-
tions,” he says. The focus on data and instrumentation is just a stage, he says; 
then, “you will necessarily go back to the hypothesis. The technique cannot 
replace and lead the human mind.” Getting more support for a small-science 
version of proteomics has been a primary goal for He.
Changing a system with such entrenched interests will be difﬁ  cult, but 
change is one thing in which He has faith. After an undergraduate degree at 
Beijing University, He was diverted by the Cultural Revolution to work as a 
porter in an agricultural chemical factory. His subsequent Ph.D. at Beijing 
Normal University (BNU) was followed by 12 years in the US. For the last 
three years of that stay he bounced between BNU and his assistant professor-
ship at the University of Texas. Finally, in 2000, he committed full time to BNU, 
where he became director of the Institute of Cell Biology.
Now part of the system, He has a chance to effect changes for his students. 
Currently, most students must do a short Master’s degree before moving to a 
different laboratory to extend this to a Ph.D. The jump between two short lab 
stints makes it almost impossible to complete a project of any signiﬁ  cance. He 
is on the central government committee that oversees such policies and is con-
ﬁ  dent that change will come in 2007. Next on the to-change list will be the 
two-year restriction on postdocs and rules preventing the youngest PIs from 
having their own Ph.D. students. Administration may not be glamorous, but the 
efforts of the genial He may be as important as any in bringing the Chinese 
university research scene to life.
HE DACHENG
Big science methods; small science thinking★
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organize science.” Therefore, “if you don’t have clear goals 5 or 10 
years off, you don’t get the money.” So far, he has resisted window-
dressing ION’s efforts or forcing his PIs to work only on diseases; 
this may explain the recent failure of his relatively modest funding 
request to support new hires. “CAS should do some applied 
research,” he admits. “It is the relative weight that is the problem.”
For those who can organize a group, however, the ￿  nal result 
may not be too different from an individual grant. Chen Ye-Guang 
at Tsinghua says the emphasis on large groups doesn’t always trans-
late into big science because “the most important discoveries are 
made by PIs not by groups.” A 973 grant on membrane traf￿  cking 
in which he participates includes eight PIs, who work on a variety 
of loosely connected topics including nuclear dynamics, exocytosis, 
endocytosis, signaling, and proteomics.
Group  funding  can  even  bene￿  t  young  PIs,  says  Fudan 
University’s Wu Chaoqun. A group grant enabled Wu’s colleague 
Huang Qiang, a young PI, to get computers for molecular simu-
lations—equipment  that  he 
could  never  afford  from  his 
individual grant.
Other  large  projects  have 
actually been initiated by ex-
patriates, including two based 
at Yale University (New Haven, 
CT). Tian Xu’s knockout mice 
at  Fudan  University  are  re-
portedly  being  made  at  4–5 
times less cost than would be 
incurred in the US (reference 
27,  and  see  sidebar),  and 
Xingwang  Deng  has  run  a 
huge plant mutant project at 
Beijing University (17).
￿￿￿￿￿￿￿￿ ￿ ￿￿￿￿￿￿
But the main argument for big science in China comes down to 
the obsession with engineering China’s continued expansion. 
Development requires new infrastructure and new coordination 
mechanisms between newly developing sectors of the economy. 
Because this is deemed to be the government’s job, “in the US 
the scientists control the money, but in China it is the govern-
ment,” says one researcher.
The government “emphasizes that scienti￿  c research must 
bene￿  t the country’s economic growth,” says Rao Zihe, who has 
been a strong proponent of some of the larger projects. “Chinese 
science has only grown in the last 10 years, and this is mainly 
because of the 973 and 863 contributions,” he says. “If you 
ignore this, it is a big mistake.” MOST, he says, “want[s] to do 
big things that are good for China’s construction.”
“China does have its own strategic concerns, for example for 
economic development, employment, and national security,” agrees 
Shi. “A government has to inject its own modi￿  cations into the 
research track. But it is really a mistake in the name of government 
regulation to invest the bulk of the money in megaprojects.”
In part, China’s current approach may be a transitional one. 
Until Chinese companies start doing more of their own research, 
the kind of applied, target-oriented research that in a developed 
Chen Zhu sees the need 
for a balance of large and 
small projects.
A step forward 
for mouse genetics
Imagine if the power of genetic screens—especially 
screens for suppressors and modiﬁ  ers of diseases—
was available in mammals. This is the future that Tian 
Xu (Yale University School of Medicine, New Haven, 
CT) is trying to bring about.
Xu has his eye on forward genetics, in which 
random mutation is used to generate or modify a 
phenotype  of  interest.  It  has  been  a  bonanza  for 
yeast, worm, and ﬂ  y researchers. Now, Xu plans to 
bring it to mice, and thus to the world of mammalian 
biology. He hopes that mutations that block obesity 
despite a high fat diet, or that block neurodegeneration 
despite a predisposing mutation, might break open 
new approaches for medical researchers.
“The  methodology  to  produce  the  mutants  is 
solid,” he says. “All we need to do is to crank up the 
space.” At the moment that space consists mainly of 
a new building with 10,000 cages at Fudan University, 
Xu’s alma mater in Shanghai. Another building, big 
enough to hold 25,000 cages, should be completed 
this year. “The speed things go in Shanghai, they 
can do this pretty rapidly,” says Xu.
Basing the project in China has worked well, 
says Xu. “For Yale, it allows us to carry out some 
experiments that are difﬁ  cult to carry out here be-
cause of limits on space and personnel,” he says. 
“For Fudan, this is a great way to train their people, 
and bring exciting scientiﬁ  c projects there. And it put 
Fudan on the map.”
Xu’s quest began with an observation about the 
shortcoming of traditional reverse genetics in mice. 
Knockouts  targeted  to  a  speciﬁ  c  gene  are  “very 
powerful,” he says, but “we are guessing what genes 
are involved, and more than 50% of knockouts don’t 
produce  the  expected  phenotype.”  The  result  is 
frustrated postdocs and wasted effort.
Mice with the RFP-marked PB transposon glow pink 
under UV light.★
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Xu’s project uses tens (and soon hundreds) of thousands of mice.
Xu with his former student Wu Xiaohui (right) and 
current student Ding Sheng (left).
This inspired Xu to bring in forward genetics, 
where you “let the genetics tell you what is interest-
ing.”  But  ﬁ  rst  he  needed  the  perfect  mutagen.  A 
chemical mutagenesis project run by NIH had been 
abandoned because it was too hard to ﬁ  nd which 
mutations were causing a phenotype.
Xu was more interested in transposons. P ele-
ments had been very effective in ﬂ  ies, Xu’s previous 
organism of interest, but did not work in mammals. 
Transposons found naturally in mammals, however, 
were  subject  to  vigorous  silencing  by  mammalian 
cells intent on preserving their genomic integrity.
Xu  concluded  that  “maybe  we  need  to  try 
something strange—something that mammals have 
never seen before.” After eight years of trial and 
error,  he  hit  upon  piggyBac  (PB),  a  transposon 
originally found in a moth. Signs of PB had been 
found in all sorts of genomes, and it turned out to 
transpose efﬁ  ciently in mouse and human cells (1). 
“Luck shined on us,” says Xu.
At Fudan, a team led by Xu’s former student Wu 
Xiaohui started hopping PB around the mice genome. 
Putting  the  PB  transposase  under  the  control  of  a 
germline promoter gave them one hop per genera-
tion at ∙70% efﬁ  ciency. So far, the team has 565 
unique insertions, 50% of them in genes, with no 
evident insertion hotspots.
The ﬁ  rst aim is to generate simple gene inser-
tions in a wild-type background. A total of 100,000 
mutants  should  ensure  coverage  of  the  ∙20,000 
mouse genes. “If we have another $30 million we 
can produce and cryopreserve mutations of 70% of 
[mouse] genes,” says Xu. “It’s not much money.”
In the ﬁ  rst batch of mutant mice, some have 
autoimmune  syndromes,  neurodegeneration,  hair 
loss, premature aging, or eye defects. Others keep 
eating but fail to grow, have social problems, circle 
counterclockwise,  or  grow  tusks.  His  technicians, 
says Xu, “are all competing to ﬁ  nd the ﬁ  rst mutation 
that will be a New York Times cover [story].”
“The students are really in heaven,” he continues. 
“The ﬁ  rst student has 75 knockouts and can choose 
the most interesting to work on.”
But that choice—what to work on ﬁ  rst—is Xu’s 
“headache right now,” he says. “We haven’t made 
up our mind yet.” He also has to restrain his large 
workforce.  “When  the  students  see  an  interesting 
phenotype they want to work on it,” he says. “But in 
ﬂ  ies we [always] ﬁ  nish[ed] a screen before deciding 
what to work on. Otherwise we will get swamped.”
That prioritizing decision may have to come be-
fore Xu is ready to release mice to others, however. 
For now he says only that release “is going to be a 
huge operation.” In terms of dates, mechanism, and 
fees, he says, “we don’t have a clear answer yet.”
Some  of  the  other  genome-wide  mutagenesis 
projects,  by  contrast,  are  already  making  mutants 
available, but notably these are in the form of mouse 
ES cells, not live mice. These other efforts in Europe, 
Canada, and the NIH in the US combine with Xu’s 
Chinese endeavor in a crazy patchwork of mutually 
overlapping projects (2). Xu has the beneﬁ  t, howev-
er, of producing live mice from day one, rather than 
being held up by the expensive conversion of ES cells 
to live mouse.
His project also starts to sound very different 
when he brings in the idea of speciﬁ  c screens. Any 
suppressor or modiﬁ  er screen would impose another 
huge burden on Xu’s already expansive project, but 
“I’m gearing up to do both at the same time,” he 
says. He does not have a timeline for starting particu-
lar screens, but says he imagines splitting his work 
equally on the whole genome knockout and disease-
suppressor screens. “It’s all resources,” he says. “The 
rest is solved.”
1.  Ding, S., et al. 2005. Cell. 122:473–483.
2.  Grimm, D. 2006. Science. 312:1862–1866.★
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The signaling duo
The path leading to Tsinghua University’s 
ﬁ  rst biology paper in Science involves 
a lost letter, swans, and two stories of 
persistence.
The senior authors of that paper, 
Meng Anming and Chen Ye-Guang, 
both got their undergraduate degrees in 
1983. Chen took the academic route, 
but had to battle through two Master’s 
degrees (one in China and another at 
Fordham University in New York City) 
before he was accepted to a Ph.D. 
program at Albert Einstein College of 
Medicine (New York, NY).
Meng, however, worked initially as 
a research assistant at China’s National 
Rice Research Institute. Under an 
exchange program, he got offers from 
at least ﬁ  ve overseas universities and de-
clined all except Wye College of London 
University (now Imperial College of Wye). 
But the leader of Meng’s institute said the 
subject at Wye—soybean breeding—was 
too distant from his current expertise in 
rice breeding, and that Meng should wait 
for help in ﬁ  nding a rice place. “I had a 
visa and ﬂ  ight ticket, but gave them up,” 
says Meng. “If I insisted, I could have 
gone, but that wasn’t my way.”
Help from the director was not 
forthcoming, and Meng’s life was at a 
standstill. Then, two years later, he found 
a letter jammed in his desk drawer. It 
was his refusal letter to David Parkin at 
Nottingham University, which he thought 
he had sent two years earlier. “So I sent 
another letter asking again,” says Meng, 
“and he said okay you can come.”
Meng was plunged into the world of 
molecular biology. “The ﬁ  rst time I used a 
pipette there I had never seen such tools 
before,” he says. For his Ph.D., he did 
DNA ﬁ  ngerprinting on, of all things, swan 
and sparrow DNA.
Back in China, 
there were no swans, 
so Meng focused on 
genetic variation in 
pigs, cattle, and chick-
ens. “The ﬁ  rst time I 
came back it was so 
difﬁ  cult to do any 
work,” he says. 
“Some of the big equipment you could 
ﬁ  nd, but small stuff you could not ﬁ  nd.” 
Lacking any absorbent tissue for South-
ern blots, he eventually resorted to the 
homemade paper used in local temples.
Next came a two-year stint in 
Georgia, which introduced him to 
zebraﬁ  sh. When Meng returned to 
China he was the ﬁ  rst in the country to 
use zebraﬁ  sh for developmental studies.
Chen, meanwhile, had done a 
postdoc in Joan Massagué’s lab at 
Memorial Sloan-Kettering Cancer Center 
(New York, NY); it yielded coﬁ  rst author-
ships on two-high proﬁ  le papers on 
TGFβ signaling (1, 2). After a couple of 
years in a tenure-track job at the Univer-
sity of California, Riverside, however, he 
was restless. “I was projecting my life 
forwards,” he says. “If I stayed at River-
side for 5 or 10 years, a secure job 
would be no problem. But if I can 
accomplish the same thing if I go back 
to China, then I should go back to China.”
In 2002, Meng’s zebraﬁ  sh experi-
ence and Chen’s TGFβ signaling back-
ground were united at Tsinghua. Meng 
had found zebraﬁ  sh Dapper2 (Dpr2); 
a related protein, Dapper1, was known 
to block Wnt signaling. But Chen and 
Meng found that Dpr2 instead blocked 
TGFβ signaling. Dpr2 binds TGFβ recep-
tors in late endosomes, thus accelerating 
their degradation and suppressing meso-
derm induction by the TGFβ protein 
Nodal (3). It is still not clear exactly how 
Dpr2 directs trafﬁ  c in this way.
Since that Science paper, Chen has 
found out how TGFβ recruits muscle and 
mesenchymal cells that build blood ves-
sels (4), and Meng led a joint effort to 
work out how a protein called Tob1 limits 
dorsal development by binding β-catenin 
(5). In addition to Dpr2 and Tob1 two-
hybrids, Meng is now doing large-scale 
transposon trapping of 
maternally expressed 
genes to generate new 
research directions.
In the meantime, 
the pair have been 
joined by an increas-
ingly stellar cast of 
colleagues in an in-
creasingly competi-
tive faculty search process. Tsinghua, 
like other universities in China, had its 
job description narrowed during the 
rule of Mao Tse-Tung. Engineering 
became the sole focus, and the Department 
of Biology was closed from 1952 to 
1983. Mu-ming Poo, acting on a part-
time basis, helped get the department 
going again in 1984.
More recent full-time arrivals in-
clude Wu Wei, who works on Wnt sign-
aling (6–8), Wu Jia-Wei, who solved 
Smad- and apoptosis-related structures 
with Yigong Shi at Princeton (9–11), and 
Li Peng, whose work has ranged from 
neuroblast asymmetry (12) to apoptosis 
(13, 14), and now to diabetes. According 
to one PI who was appointed in 2002, 
“This is all happening very fast. If I 
applied for [a job in] this department, 
now I’m not sure I could get it.”
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country  would  be  done  by  companies  is  instead  the 
responsibility of the government. “In the future,” says CAS’s 
Chen, “more emphasis should be put on enhancing the re-
search and development by enterprises.” This may in turn lead 
to greater freedom for academics.
The ￿  nal argument is based on the politics of funding. At budget 
time, says Rao Zihe, everyone tries to get money independently: 
“MOST tries hard; the Ministry of Education tries hard; NSFC tries 
hard.” But protests from abroad have the potential to “stop MOST 
from getting money from the budget.”
Lu has a different opinion. “They think overseas scientists 
may not understand the politics, the societal needs—if you 
don’t get it this way the money will never come.” But, he 
says, “there is a principle: you have to do it by fair, competi-
tive review. We can debate the details, but the principle is 
the principle.”
MOST has been responsive to some of the expatriates’ com-
plaints on individual cases, says Lu, “but in the end you need to 
institutionalize,  not  rely  on 
someone’s  goodwill.”  He 
thinks  that  MOST  supports 
peer review, but “if you have 
a  commitment  of  10  or  20 
years,  you  need  an  interim 
review  to  correct  mistakes. 
It’s that kind of mechanism 
that is still lacking.”
Shi  and  Lu  stress  that 
they are not trying to impose 
the  US  system  on  China. 
“No  one  knows  the  best 
funding system for China,” 
says Shi. “The current fund-
ing system has its reasons, 
but we must constantly think 
about how to improve it.”
Shi sees China’s problem as somewhat circular: recruitment 
at the top level is needed to improve the scienti￿  c consensus on 
funding; and a scienti￿  c consensus on funding is needed to im-
prove the research environment and thus recruitment.
“If they can solve both of these problems, scienti￿  c develop-
ment could be tenfold faster,” he says. “If someone thinks China’s 
research is really going well and cannot maintain this rate, this is 
absurd. China’s research can only be better, and it will be better. 
I cannot predict what China will be in 20 years.”
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Princeton’s Yigong Shi says 
government control should not 
overwhelm scientiﬁ  c diversity.
PLAYING THE GAME  Cooperation is key in Chinese science.